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ABC ATP-binding cassette 
AEC Sodium POE 10 fatty alcohol ether carboxylate 
ATCC American type culture collection 
AML Acute myeloid leukemia  
AKT Protein kinase B 
ALDH1 Aldehyde dehydrogenase 1 
β-actin Beta-actin 
BCA Bicinchoninic acid 
BCIP 5-Bromo-4-chloro-3-indolyl phosphate 
BSA Bovine serum albumin 
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CAM Chorioallantoic membrane 
CSC Cancer Stem-like Cell 
CD133 Prominin-1 
CD24 Cluster of differentiation 24 
CD44 Cluster of differentiation 44 
c-Met Mesenchymal-epithelial transition factor and membrane 
receptor 
CO Control 
CO2 Carbon dioxide 
Dapi 4'-6-diamidino-2-phenylindole 
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DTT Dithiothreitol 
dsDNA Double-stranded DNA 
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EDD Embryonic Development Day 
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EDTA Ethylenediaminetetraacetate 
EMT Epithelial-mesenchymal-transition 
FCS Fetal calf serum 
FGF Fibroblast growth factor 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GEM Gemcitabine 
HCl Hydrochloric acid 
H&E Hematoxylin and eosin 
HEPES 4-(2-Hydroxyethyl)-1-piperazineethanesulfonic acid 
IF Immunofluorescence  
IgG Immunoglobulin G 
Hh Hedgehog 
IHC Immunohistochemistry 
Ihh Indian hedgehog 
mRNA Messenger RNA 
NaCl Sodium chloride 
NBT Nitro blue tetrazolium 
p53 Tumor protein p53 
PDA Pancreatic Ductal Adenocarcinoma 
PBS Phosphate buffer solution 
PCR Polymerase chain reaction 
PFA Paraformaldehyde 
pH Potential of hydrogen 
Ptch Patched 
SCID Severe combined immunodeficient 
siRNA, Small interfering RNA  
Shh Sonic hedgehog 
siCO Small interfering RNA Negative control 
Smo Smoothened 
RT-PCR Reverse transcription-polymerase chain reaction 
RNA Ribonucleic acid 
RT Room temperature 
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SD Standard deviation 
SDS Sodium dodecyl sulfate 
TBS Tris-buffered saline 
UV Ultraviolet 
UTR Untranslated region 
VEGF Vascular endothelial growth factor 
WHO World Health Organization 
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Units 
 
°C  centigrade or degree celsius 
cm centimeter 
g gravitational acceleration (9.81ms-2) 
h hours 
KDa kilo Dalton 
L liter 
M molar [mol/L] 
mA milliampere 
min minutes 
mL milliliter 
mm millimeter 
mM millimolar 
µ micro 
µg micrograms 
µL microliter 
µm micrometer 
µM micromolar 
ng nanogram 
nM nanomolar 
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2. INTRODUCTION 
2.1 Pancreatic cancer and therapy management 
2.1.1 Epidemiology and demographics 
As a malignant disease with a very bad prognosis, pancreatic cancer is rising to the 
third leading cause of cancer death among both men and women in the United States 
[1]. In 2012, around 16,700 patients were diagnosed with pancreatic cancer in 
Germany. According to a recent study, the major part of the new cases have been 
observed in Europe (30.7%), China (19.5%), and North America (14%) [2]. Besides, 
the incidence of pancreatic cancer is still expanding worldwide during the past years. 
It is assumed that pancreatic cancer would turn into the second leading lethal cancer 
after lung cancer in the US, surpassing colorectal, breast, and prostate cancer by 2030 
[3]. Around the world, 338,000 new pancreatic cancer cases were diagnosed and 
330,000 died of this disease approximately every year [2]. The high morbidity and 
mortality underlines the pressure demand of studying this disease. The risk factors for 
pancreatic ductal adenocarcinoma (PDA) include but are not limited to ethnicity and 
race [4], medical conditions [5], history of pancreatitis, obesity, helicobacter pylori 
infection, hepatitis B, human immunodeficiency virus (HIV), cirrhosis, hereditary [6], 
Lynch syndrome, Peutz-Jeghers syndrome, family history of pancreatic cancer, Li-
Fraumeni syndrome, tobacco use, alcohol use, high fat and cholesterol diet [7]. Pain 
and weight loss are the most typical symptoms of pancreatic cancer, while the most 
common clinical sign is jaundice. One review has revealed the following frequency 
of signs and symptoms in patients with PDA, which is shown is Table 1 [8].  
Table 1: Symptoms and signs in patients with PDA 
Sign and symptom Proportion Sign and symptom Proportion 
Weakness/fatigue (asthenia) 86% Weight loss 85% 
Loss of appetite (anorexia) 85% Dark urine 59% 
Abdominal pain 79% Jaundice 56% 
Nausea 51% Back pain 49% 
Diarrhea 44% Vomiting 33% 
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However, the giving signs and symptoms mentioned above are not special for 
pancreatic cancer diagnosis. That is the major reason why pancreatic cancer is 
mainly diagnosed in an advanced stage. 
2.1.2 Pathology and staging 
PDA is the most common type of pancreatic malignancies, attributing more than 85% 
in all types of pancreatic cancer [9]. Therefore, the name “Pancreatic Cancer” is 
regularly used to refer to PDA [10]. PDA is an epithelial tumor that emerges from 
pancreatic duct or ductal cells, from which the overwhelming majority of pancreatic 
neoplasms originate (Figure 1). The most common precursor lesion is PanIN, it was 
divided into three grades: PanIN-1, PanIN-2, and PanIN-3 according to the degree of 
epithelial atypia. 
 
Figure 1: Majority of PDA cells originate from pancreatic duct or ductal cells (Adapted from [9]) 
An attempt of staging PDA should be made after a verified or highly suspected 
diagnosis of PDA. Based on the 7th edition of the American Joint Committee on  
Table 2: American Joint Committee on Cancer staging system 
 AJCC stage Anatomic stage Proportion Median survival time T N M 
Early stage 
Stage 0 Tis N0 M0 
10% 17-23 months 
Stage IA T1 N0 M0 
Stage IB T2 N0 M0 
Stage IIA T3 N0 M0 
Stage IIB 
T1 N1 M0 
T2 N1 M0 
T3 N1 M0 
Stage III T4 Any N M0 30% 8-14 months 
Advanced 
stage Stage IV Any T Any N M1 60% 4-6 months 
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Primary Tumor (T); T0: No evidence of primary tumor; Tis: Carcinoma in situ; T1: Tumor limited to 
the pancreas, 2 cm or less in greatest dimension; T2: Tumor limited to the pancreas, more than 2 cm in 
greatest dimension; T3: Tumor extends beyond the pancreas but without involvement of the celiac axis 
or the superior mesenteric artery; T4: Tumor involves the celiac axis or the superior mesenteric artery; 
Regional Lymph Nodes (N); N0: No regional lymph node metastasis; N1: Regional lymph node 
metastasis; Distant Metastasis (M); M0: No distant metastasis ;M1: Distant metastasis (Adapted from 
[10]). 
Cancer (AJCC), the tumor-node-metastasis (TNM) staging system is most often used 
for staging pancreatic cancer, which is shown in Table 2 [10]. All the patients in 
stage IV and patients in stage III with tumor spread into surrounding tissues are 
defined as advanced stages. Patients in advanced stages, which account for about 60-
90% among all PDA patients, indicate a poorer prognosis and less survival time.  
2.1.3 Current therapy for pancreatic cancer 
There are five types of standard treatments available for PDA patients: surgery, 
radiation therapy, chemotherapy, chemoradiation therapy and targeted therapy. In 
spite of developing studies of the pancreatic cancer biology, advancement in early 
diagnosis and the increase of pancreatic cancer centers, the origin of this disease is 
still not fully clear and the prognosis of pancreatic cancer remains extremely poor 
[11]. Even now, only complete surgical resection of the tumor is the definitive 
therapy for PDA. Nevertheless, the clinical outcome remains rather pessimistic, 
because only around 10-20% of the PDA cases have indication to undergo 
surgical resection [12]. To extend survival time or improve quality of life, 
chemotherapy is implied in the treatment of PDA in all cases [13, 14]. Gemcitabine is 
considered as the standard chemotherapy drug in the pancreatic cancer treatment [14]. 
After gemcitabine was first synthesized during the early 1980s it showed efficacy to 
kill leukemia cells in the preclinical studies [15]. In 1993, gemcitabine was first 
applied to treat pancreatic cancer [16]. Gemcitabine has been the cornerstone 
chemotherapeutic agent for pancreatic adenocarcinoma based on clinical benefit 
compared with 5-FU [17]. Since the approval of gemcitabine monotherapy as first-
line treatment by the Food and Drug Administration (FDA) in 1996, gemcitabine and 
several combination therapies (for example: erlotinib, 5-FU and cisplatin) based 
on gemcitabine have been widely used in the treatment of many types of cancer, 
including breast cancer, lung cancer, ovarian cancer and pancreatic cancer [18-21]. 
Chemically gemcitabine is a nucleoside analog in which the hydrogen atoms on the 2' 
carbon of deoxycytidine are replaced by fluorine atoms (Figure 2).  
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Figure 2: Molecular structure of gemcitabine 
4-amino-1-(2-deoxy-2, 2-difluoro-β-D-erythro-entofuranosy l) pyrimidin-2(1H)-on. Fluorine atoms 
replace the hydrogen atoms on the 2’ carbon of deoxycytidine. 
The major mechanism of gemcitabine is the inhibition of DNA synthesis by 
incorporating of gemcitabine diphosphate (dFdCTP) into DNA. An additional 
mechanism of gemcitabine is self-potentiation by binding the active site of 
ribonucleotide reductase, decreasing activity and the synthesis of deoxy 
ribonucleotides, which is required in DNA replication and reparation [22]. In 1997, 
the results of a phase II trial were very encouraging. Compared to pancreatic cancer 
patients treated with 5-flurouracil (5-FU), patients treated with gemcitabine had a 
significantly better clinical response (from 4.8 to 23.8%) as well as a significant 
increase of median survival time (from 4.41 to 5.65 months) and survival rate (from 2 
to 18%) [23]. In addition, patients tolerated the mild toxicity of gemcitabine well. 
From then on, more and more clinical and laboratory experiments demonstrated that 
gemcitabine was an effective chemotherapy drug for pancreatic cancer. Surprisingly, 
all efforts trying to improve the effects of gemcitabine in the clinic failed to show 
synergistic effects for example: gemcitabine plus erlotinib [24], 5-FU [25] or 
cisplatin [26]. Until now, gemcitabine is still considered as one of the standard and 
most important cytotoxic drugs in the treatment of advanced pancreatic cancer and 
widely used in the clinic. However, less than 25% of PDA patients benefit from 
gemcitabine treatment in total and the overall survival rate is still not improved 
remarkably. The current agents that are the standard of care in this setting are 
gemcitabine, or a combination of 5-FU and leucovorin. FOLFIRINOX (5-FU, 
leucovorin, irinotecan, oxaliplatin) illustrated a survival benefit for patients with 
metastatic or unresectable PDA despite its increased toxicity compared to 
gemcitabine alone [27]. Radiotherapy presents an alternative adjuvant treatment but 
the benefit of radiation in PDA is somewhat controversial because randomized trials 
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have suggested inconsistent outcome in locally advanced pancreatic cancer [13]. 
Therefore, new and better therapeutic options are required. 
2.2 Cancer stem-like cells 
Cancer stem-like cells (CSCs), also known as cancer-initiating cells or tumor-
initiating cells [20] are defined as a group of cells within a tumor mass that possesses 
the capability of unlimited self-renewal and resistance to standard chemotherapy in 
both primary tumor and metastases and is able to reconstitute tumor growth in vitro 
and in vivo [28-32]. The stem-like characteristics of CSCs are sufficient to assimilate 
them into stem cells. Moreover, the discovered experimental and clinical features of 
metastatic cancer cells are very close to the established features of stem cells [21]. 
The fundamental hypothesis implies that CSCs drive metastasis and recurrence even 
when all signs of the cancer have been relieved by surgery or conventional 
chemotherapy (Figure 3). By targeting CSCs, cancer could regress due to 
differentiation and/or cell death [33]. 
 
 
Figure 3: The cancer stem-like cell hypothesis  
The cancer stem-like cell (CSC) hypothesis implies that CSC can generate a tumor, because this small 
group of cancer cells is capable of enormous proliferative potential and self-renewal properties. This 
theory suggests that targeting these subpopulations of cancer stem-like cells could destroy the tumor 
long-term without the necessity to fight the whole tumor (Modified from [33]). 
In 1994, Lapidot and colleagues first identified CSCs in acute myelogenous leukemia 
(AML) by using cell-surface protein markers to identify a small group of stem-like 
   Tumor response following
conventional cancer therapies Tumor recurrence with
expansion of CSC pool
Heterogeneous
   tumor cells
     Treatment with
CSC-targeted therapy
Tumor regression
Cancer stem-like cell (CSC)
Nontumorigenic cancer progenitor cell
Nontumorigenic cancer cell
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cells and detected that leukemic cell growth could be induced only by CD34+/CD38- 
AML cells in SCID mice. These subpopulations of cells were also supported to have 
the capacities of self-renewal and differentiation in mouse models. In 2003, CSCs 
were first discovered in solid tumor by Al-Hajj and colleagues [34]. 
ESA+/CD44+/CD24- cells obtained from primary human breast cancer were identified 
as breast CSCs because these cells exhibited greater tumorigenicity than other cancer 
cells. Subsequently, various kinds of solid tumor CSCs were identified in brain, lung, 
colon, liver, prostate and ovarian cancers [35-39].  
2.2.1 Pancreatic cancer stem-like cells  
Increasing evidence has cropped up to prove the presence of CSCs in pancreatic 
cancer [40, 41]. In 2007, Li and colleagues were the first to identify 
CD44+/CD24+/ESA+ cells as CSCs in pancreatic cancer [42]. These cells accounted 
for only less than 1% of total PDA cells and showed the stem cell properties of self-
renewal and generating differentiated progeny. Hermann and colleagues proved that 
CD133+ cells were highly resistant to standard chemotherapy and exclusively PDA 
tumorigenic [43]. Afterwards, various pancreatic cancer stem-like cell sub-population 
were identified using different methods. For instance, side population (SP) cells 
which can efflux Rhodamine 123 or Hoechst 33342 were found possessing features 
of cancer stem-like cells in pancreatic cancer [44]. CD24+/CD44+ [45] or c-Met+ [46] 
or Gdeghigh [41] were identified as the pancreatic cancer stem-like cell surface 
markers. Nanog and nuclear transcription proteins Oct4 were also proved to be 
associated with stemness of pancreatic cancer cells [47]. Cellular markers such as c-
Met, ESA, EpCAM, ALDH1, nestin, CD24, CD44, CD133 and Lgr5 have been used 
to characterize pancreatic CSCs [41, 42, 48-50]. They possess several characteristics 
of carcinogenesis process such as self-renewal, proliferation, immortality and many 
signaling pathways. Signaling pathways like Sonic hedgehog, PTEN, Notch, 
PI3K/AKT and Wnt are altered by pancreatic cancer stem-like cells [51, 52]. The 
regulatory mechanisms triggering the CSCs are poorly defined for most types of 
cancer, it has been implicated that several key developmental signaling pathways 
related to normal stem and progenitor functions play important roles in CSCs 
regulation. In addition, sphere and colony formation assays are considered as partly 
mimic tumorigenicity in vitro [53]. 
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2.3 Hedgehog signaling and pancreatic cancer 
2.3.1 Introduction 
In 1995, the Nobel Prize in Medicine was awarded for discoveries concerning “the 
genetic control of early embryonic development”. Two Nobel laureates, Eric F. 
Wieschaus and C. Nüsslein-Volhard, isolated mutations in genes that control the 
segmentation pattern of Drosophila melanogaster embryos. Their mutagenesis screen 
discovered that loss of a gene function later to be called Hedgehog. There are three 
Hedgehog (Hh) genes named by the prefixes Indian (Ihh), Desert (Dhh) and Sonic 
(Shh) [54]. After translation as an around 46-kDa precursor, in addition to the 
removal of the signal peptide, Hh proteins are further processed by internal cleavage 
to generate two fragments. The 19 kDa N-terminal fragment (N-Hh) has all the 
known signaling activity of Hh. While the 25 kDa C-terminal fragment (C-Hh) 
undergo post-translational modifications by adding cholesterol at the C-terminus of 
N-Hh (N-Hhchol) and engage in this processing reaction [55-63] 
Canonical Hh pathway activation is originated by the binding of secreted Hedgehog 
molecules to a transmembrane receptor called Patched (Ptch), which relieves its 
inhibition on Smoothened (Smo), another transmembrane protein that is suppressed 
by the Ptch in the absence of Hh. Therefore, Smo operates its function only when Hh 
is present. Smo transduces the signal intracellularly through Gli zinc finger 
transcription factors. Consequently, activating Smo initiates an intracellular signaling 
cascade multiplying the formation of activated forms of Gli2 and Gli3, which directly 
induce Gli1. Three transcription factors composed Gli family and act as key 
mediators of Hh signaling in cancer by regulating the expression of target genes in 
which only Gli1 is a solely full-length transcriptional activator. Gli2 and Gli3 can be 
partly processed into truncated repressor forms [64, 65]. Finally, Suppressor of Fused 
(Sufu), is a key negative regulator of Hh signaling activity, controls the activation of 
the Gli transcription factors as a tumor suppressor gene. Sufu could prevent Hh 
pathway activation by directly binding the Gli transcription factors and inhibiting 
their translocation to the nucleus [66]. The binding of the Gli proteins with Sufu in 
the cytoplasm will promote processing and/or degradation of them and thus inhibit 
Hh signaling [67].(Figure 4). 
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Figure 4: Mammalian Hedgehog (Hh) signaling 
A. Hh ligand protein precursors are autoproteolytically cleaved to produce an N-terminal protein that 
goes through dual lipid modification, consisting of an N-terminus and a C-terminal cholesterol group, 
which advances the binding of Hh to sterol-rich membrane microdomains to restrict mobility. Then 
Dispatched in synergy with Scube2 mediates the release of active Hh ligand. B. In the absence of Hh, 
Ptch represses Smoothened (Smo), inhibiting its ciliary localization. In this case, Gli proteins are kept 
in a complex with Sufu at the ciliary tip. The recruitment of glycogen synthase kinase 3β (GSK3β), 
protein kinase A (PKA) and β-transducin repeat-containing protein (β-TrCP) to this complex lead to 
partial proteasomal degeneration to form Gli transcriptional repressors (GliR) that translocate to the 
nucleus and inhibit Gli target genes. C. In the presence of Hh, the inhibition of Smo is relieved by 
binding of Hh to its receptor Ptch1. Activation of Smo assists the release of Gli from Sufu, and then 
full-length Gli activators (GliA) transfer from plasmid to the nucleus and active Hh target genes 
(Adapted from Ref. [68]). 
2.3.2 The Hedgehog signaling in pancreatic cancer 
Hh signaling is an evolutionarily-conserved pathway essential for self-renewal and 
cell fate determination and a key pathway critical in embryonic development, stem 
cell biology and tissue homeostasis, cellular metabolism, synapse formation and 
nociception [69-73]. Sonic hedgehog signaling is conserved in vertebrates and highly 
active during mammalian development, but this signal usually shuts down after birth 
[74]. In recent years, aberrant activation of Shh signaling has been implicated in 
multiple aspects of cancer progression, from initiation to metastasis [64], including 
the maintenance of CSCs [68]. The dysregulation of Shh signaling is also known to 
drive several types of cancer, including basal cell carcinoma, breast, ovarian, lung, 
prostate, liver, gastrointestinal and bladder cancer [64, 65, 75-77]. Moreover, recent 
studies reveal that Hedgehog inhibition significantly prolonged survival in a mouse 
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model of pancreatic cancer [78] and inhibited pancreatic cancer invasion and 
metastatic spread [54, 78-83]. The precise mechanism of how Hh acts in pancreatic 
cancer is not completely clear yet may be caused by autocrine signaling, paracrine 
signaling or selective activation of cancer initiating stem cells. Additionally, mutant 
Kras activates Gli1 in pancreatic cancer [84-86], and Gli activity could be regulated 
by altering the activation of pathways which interact with Hedgehog signaling 
through intercellular cross talk, such as the mitogen-activated protein kinase 
RAF/MEK signaling pathway [54]. 
2.4 Cholesterol synthesis and metabolism in cancer 
2.4.1 Normal cholesterol homeostasis 
Cholesterol is mainly synthesized in the liver. Nevertheless, genome and/or 
transcriptome alterations cannot directly reflect cholesterol homeostasis, since lipids 
are not genetically encoded [87]. Cholesterol is transported to cells over the body 
through the bloodstream as a form of low-density lipoprotein (LDL)-bound [88, 89]. 
LDL is transported into cells by clathrin-mediated endocytosis and hydrolyzed to free 
cholesterol molecules after being transported to lysosomes through endocytic 
pathway. Afterwards, the free cholesterol molecules are transported to the cell 
membrane and cell membrane-bound organelles [87, 88, 90]. A tightly controlled 
protein network regulates cholesterol homeostasis, including its biosynthesis, import, 
export, metabolism and esterification [87]. Liver X receptors together with sterol 
regulatory element-binding protein transcription factor 2 (SREBF-2) play important 
roles in the regulation of cholesterol homeostasis [87, 90]. Endoplasmic reticulum 
(ER) cholesterol level plays a role as a sensor for intracellular cholesterol 
homeostasis. Sterol regulatory element binding protein 2 (SREBP-2) is translocated 
from ER to Golgi and then to the nucleus when ER cholesterol level decreased and 
this process results in transcription of genes involved in cholesterol synthesis, such as 
HMG-CoA. It was proved that SREBP-2 activity had a strong association with cell 
viability in human prostate tumor cells, on the other hand, cholesterol synthesis can 
also be turned off by increased intracellular cholesterol level, meanwhile assists 
cholesterol export via activation of LXR receptors by oxysterols [91]. 
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2.4.2 Role of cholesterol metabolites in cancer development 
The metabolic alteration from catabolic to anabolic metabolism has been considered 
as a classic hallmark of cancer [92]. With its complex biosynthesis and metabolism 
[89], cholesterol is not only important in the pathogenesis of cardiovascular diseases 
and diseases of brain vascular, but has been also involved in diabetes, dementias, and 
development of cancer types [90, 93, 94]. Cholesterol intake is indicated to increase 
the risk of breast cancer and induce tumor growth and metastasis in mouse breast 
cancer model by upregulating the level of oxysterol 27-hydroxycholesterol (27HC), 
which is a main cholesterol metabolite (Figure 5). Besides, cholesterol is the 
precursor of estrogen, and high blood level of estrogen is associated with an 
increased risk of breast cancer  [96]. 
 
 
 
 
 
 
 
 
 
Figure 5: Potential signaling of cholesterol in cancer 
Importantly, cholesterol is also the precursor of steroidogenesis, which can produce 
androgen, and the activation of androgen receptor by androgen results in prostate 
cancer cell proliferation and invasion [95, 96]. The mevalonate pathway is aberrant 
upregulated in prostate cancer cells, clinical and experimental evidence indicated a 
positive association between higher serum cholesterol level and higher risk for 
several cancer types [97-99], a 10 mg/dL increase in cholesterol contributed to a 9% 
rise in prostate cancer recurrence [99]. PDA cells are also highly dependent on 
cholesterol uptake through low-density lipoprotein receptor [100]. In PDA cells, 
reduction of cholesterol uptake or interruption of its distribution by blocking low-
density lipoprotein receptor (LDLR), result in inhibition of cancer cell proliferation 
and ERK1/2 survival pathway. [101]. However, the role of cholesterol metabolites in 
carcinogenesis and tumor development needs expansion as well as the involvement 
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of different metabolites in various cancer types. Targeting the biosynthesis, transport, 
or metabolism of the cholesterol homeostasis pathways are options for controlling 
cancer development. 
2.4.3 Targeting cholesterol synthesis in cancer 
There are more than 15 proteins in cholesterol synthesis pathway, giving multiple 
potential targets to interrupt the cancer cellular pathway [88]. The proteins in the 
upstream process of cholesterol biosynthesis, such as mevalonic acid, farnesyl 
pyrophosphate and geranylgeranyl pyrophosphate, are essential for lipid modification 
and various cancer related signaling, including GPCR, PI3K, Akt, Ras and other 
GTPases signaling. HMG-CoA reductase is one of the most important key proteins in 
cholesterol synthesis, the chemotherapeutic potential of targeting these cholesterol 
synthesis genes has been extensively explored preclinically [102-104]. A recent 
example is that modulated cholesterol levels control cancer development, involving a 
short-term biomarker simvastatin, which reduces breast cancer recurrence by 
downgrading serum estrone sulfate levels [105]. However, long-term studies are 
needed to confirm this observation. Bisphosphonates and tocotrienols are examples 
of downstream inhibitors of the cholesterol synthesis pathway, which in preclinical 
studies suppress cultured cancer cells and tumor growth similar to the observation 
with statins [106, 107]. Thus, preclinical studies suggest that targeting the cholesterol 
synthesis pathways could be useful for controlling cancer. 
2.4.4 Role of cholesterol in Hh signaling 
HMG-CoA reductase controls the conversion of HMG-CoA to mevalonic acid, which 
is the precursor for the biosynthesis of several fundamental end-products including 
cholesterol, isoprenoids, dolichol, ubiquinone, and isopentenyladenine [108]. All of 
these end-products play crucial roles in promoting carcinogenesis. Statins are  
competitive inhibitors of HMG-CoA reductase widely used as cholesterol-lowering 
medications [109]. Cholesterol plays an important role in the Hh pathway because of 
its covalently modification with active Hh proteins, making this post-translational 
modification unique among all known proteins [56]. After synthesized as 49 kDa 
premature proteins, the precursors of Hh proteins firstly pass through a signal peptide 
cleavage after reaching the ER to create a C-terminal autoprocessing domain (Hh-C) 
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and an N-terminal signaling domain (Hh-N). The C-terminal has auotoproteolytic 
activity, which catalyzes an intramolecular splicing reaction by attaching a 
cholesterol moiety to the newly produced Hh-N C-terminus. The cholesterol-
modified N-terminal domain further undergoes palmitoylation at the N-terminus 
producing a highly hydrophobic and activity protein [110]. Cholesterol is essential to 
maintain this cleavage process and the activity of Hh proteins, which play an 
important role in CSCs, suggesting that simvastatin may contribute to the elimination 
of pancreatic CSCs via Hedgehog pathway; however, to our knowledge, the 
mechanisms involved in the ant-proliferative and anti-CSC actions of simvastatin 
have not yet been fully studied. Hh requires cholesterol to enable active forms and 
function. Thus, lowering cholesterol levels by statin drugs such as simvastatin is a 
crucial and possible mechanism for inhibiting Hedgehog signaling and cancer.  
2.5 The role of statins in cancer  
2.5.1 Introduction of statin 
The first statin is mevastatin, which was isolated by Akira Endo from the fungus 
Penicillium citrinium in 1976 [111]. In 1979, lovastatin was isolated from a strain of 
the fungus Aspergillus terreus by Hoffman and colleagues. During developing and 
researching lovastatin, simvastatin was synthesized from a fermentation product of A. 
terreus by scientists from Merck, which is a more efficient HMG-CoA inhibitor. 
[112]. There are currently seven types of statins approved by the FDA, namely 
pravastatin, fluvastatin, atorvastatin, lovastatin, rosuvastatin, pitavastatin and 
simvastatin (Figure 6). Notably, cerivastatin, which was approved in 1997, was 
withdrawn from the market worldwide in 2001 because the use of it was linked to 
rhabdomyolysis, which lead to kidney failure.  
 
Figure 6: Structure of the lactone and hydroxyl acid form of simvastatin (Adapted from [113]) 
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2.5.2 Effect of statins in cancer metabolism  
As the rate-limiting enzyme, the inhibition of HMG-CoA reductase by statins 
prevents the transformation of HMG-CoA to mevalonate in the mevalonate pathway, 
and consequently prevents the formation of mevalonate and products derived from it. 
(Figure 7) [108].  
 
Figure 7: Statins inhibit the conversion of HMG-CoA to mevalonate 
Statin’s inhibition of mevalonate pathway decrease levels of both mevalonate and its downstream 
products (Adaped from Ref. [114]).  
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A lot of products from the mevalonate pathway are required for important cellular 
functions, including protein synthesis, membrane integrity, cell signaling, and cell 
cycle progression [108, 115]. Statin’s interruptions of these processes in tumor cells 
may lead to control of tumor initiation, growth, and metastasis [115]. Inhibition of the 
mevalonate pathway by statins has the potential to decrease the cancer risk and 
prevent the recurrence of aggressive cancers. The localization and function of 
mevalonate downstream products are dependent on isoprenylation and the inhibition 
of downstream products may mediate the pleiotropic effects of statins, such as Ras, 
Rho, Rac and small GTP-binding proteins. It was found that statin showed 
antiproliferative, pro-apoptotic and anti-invasive effects in preclinical studies and 
animal models of different cancer types. Importantly, statins exhibited targeted action 
mainly in cancerous cell lines compared to non-malignant cells. Recent findings also 
indicated that statins had synergistic effects when they were used together with 
chemotherapeutic agent and radiotherapy. Same effect was also detected in 
chemotherapy-resistant tumors. These observed synergistic effects of statins to both 
chemotherapy and radiation might be mediated by arresting cell cycle progression at 
G0/G1 phase [116-119]. Likewise, population-based clinical studies also suggested 
that patients were benefited from statin treatment in many tumor types [120-126]. 
2.5.3 Anti-cancer efficacy of statins 
In 1988, the association between cancer risk and statin use in animal model was 
firstly observed by MacDonald and his colleagues. They found that more lovastatin 
use was related to a higher incidence of pulmonary cancer [127]. Likewise, 
simvastatin induced follicular adenomas in rats [128]. However, in these studies 
statin-related cancer risk was limited too much higher dosages than that used in 
clinical treatment. Lots of studies in vitro found that statins had anti-carcinogenic 
activities. The promising antitumor effects of statins in preclinical studies have 
inspired investigations into their potential consequences as an antitumor agent in 
animal models. There are numerous studies about different satins in preclinical 
studies. Among all statins, simvastatin was suggested to exert the highest tumor-
suppressive effects in vitro and in vivo [129, 130].  
A mouse melanoma model proved that simvastatin inhibits tumor growth and 
metastasis. Furthermore, simvastatin was suggested to significantly improve the 
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survival rate in a mouse melanoma metastasis model by inhibiting Rho signaling 
pathways [131]. Borahay MA and his/her colleagues suggested that treatment with 
simvastatin (20 mg/kg/day) reduced expression of the proliferation marker Ki67 in 
xenograft tissue from uterine fibroid tumors [132]. Investigators suggested that 
simvastatin inhibits tumor growth at a high dosage (40 mg/kg/day) in breast cancer 
and implied that this effect may be related to simvastatin’s inhibition of CSCs [133]. 
Similar result was found in another study, in which simvastatin reduced metastasis 
formation in vivo [134]. In the study of V. Fendrich and colleagues, simvastatin could 
significantly delay progression of pancreatic cancer in mice. These results indicate 
that administration simvastatin could be an effective strategy for the inhibition of 
cancer progression. The association between statins and cancer risk regarding 
different types of cancer in vivo was summarized in Table 3. 
Table 3: The related anti-cancer effect of simvastatin in vivo 
Effect Statin Tumor  Target Ref 
Inhibition of proliferation      
Anti-metastasis effect  
Anti-metastasis effect  
Inhibition of proliferation  
Induction of apoptosis 
Anti-invasion effect  
Inhibition of proliferation  
Simvastatin 
Fluvastatin 
Simvastatin 
Simvastatin 
Simvastatin 
Simvastatin 
Metastatic 
melanoma 
Breast cancer 
Uterine 
leiomyoma 
Pancreatic cancer 
Breast cancer 
Rho 
FOXO3a 
Akt 
HMG-CoA 
CSCs 
[131] 
[134] 
[132] 
[135] 
[133] 
2.5.3 Clinical safety and efficacy of statins 
Statins can have antitumor effects and synergize with certain chemotherapeutic 
agents to decrease the development of multidrug resistance [102, 136]. Several 
clinical trials have examined the potential chemo preventive and therapeutic efficacy 
of statins (Clinical trial identifier: NCT02534376, NCT02360618, NCT00584012, 
NCT01110785). Clinical studies involved in interaction between the risk of cancer or 
cancer-related mortality and statin use has been lasting for many years, however, only 
a few convincing evidences were found. Epidemiologic findings of the association 
between statin use, cancer risk and cancer prognosis have revealed different results. 
Many clinical studies indicated that statin use could prevent carcinogenesis and 
benefit the survival of cancer patients [121, 123-125]. Recently, association between 
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use of statin and liver cancer was also evaluated in a nested case-control study [137]. 
K.A. McGlynn and colleagues suggested that the use of statin was associated with an 
increased risk of liver cancer. However, more studies found that the statin use could 
decrease the risk of Hepatocellular carcinoma (HCC) [120] [137, 138]. Meta-analyses 
on randomized statin trials also suggested that the use of statins was associated with 
lower risk of primary liver cancer [122]. A retrospective cohort study showed a 
significant difference in survival between patients who received low-intensity doses 
of simvastatin and those who received moderate high-intensity doses. Statins are 
normally well tolerated despite the side effects after long-term administration, mainly 
myopathy, rhabdomyolysis and hepatotoxicity. The association between statin use 
and cancer risk and/or mortality obtained from clinical findings regarding different 
types of cancer is summarized in Table 4. 
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 Table 4: Summary of published clinical studies using statins as anticancer therapy 
Atorvastatin (A), Cerivastatin (C), Fluvastatin (F), Lovastatin (L), Pitavastatin (Pi), Pravastatin (Pr), 
Rosuvastatin (R) and Simvastatin (S). 
Statin Cancer Influence on cancer risk, 
mortality and survival 
Ref 
S 
A, C, F, Pr, R, S 
F, L, Pr, R, S 
A, F, Pr, R, S 
A, C, F, L, Pi, Pr, R, S 
A, F, L, Pr, R, S 
A, C, F, L, Pi, Pr, R, S 
S, L 
All statins 
A, F, L, Pr, R, S 
A, F, L, Pr, R, S 
A, F, Pr, R, S 
A, L, Pr, R, S 
A, F, L, Pr, R, S 
A, C, F, L, Pr, R, S 
S 
A, S 
A, F, L, Pr, R, S 
All statins 
A, F, L, Pr, R, S 
A, C, F, L, Pr, R, S 
A, F, L, Pr, R, S 
All statins 
A, F, Pr, S 
A, C, F, Pr, R, S 
A, F, L, Pr, R, S 
A, F, L, Pr, R, S 
A, F, Pr, S 
A, F, L, Pr, R, S 
A, F, Pr, R, S 
A, C, F, L, Pr, R, S 
A, F, L, Pr, R, S 
All statins 
A, C, F, L, Pr, R, S 
S, L 
A, C, F, L, Pr, R, S 
A, F, Pr, R, S 
A, F, Pr, R, S 
A, C, F, L, Pr, R, S 
A, F, L, Pi, Pr, R, S 
A, C, F, Pr, R, S 
Pancreatic cancer 
Liver cancer 
Liver cancer 
Pancreatic cancer 
Liver cancer 
Brain cancer 
Colorectal cancer 
Pancreatic cancer 
Colorectal cancer 
Liver cancer 
Prostate Cancer 
Esophageal cancer 
Breast cancer 
Kidney cancer 
Kidney cancer 
Colorectal cancer 
Pancreatic cancer 
Prostate cancer 
Prostate cancer  
Pancreatic cancer 
Endometrial Cancer 
Esophageal cancer 
Prostate cancer 
Prostate cancer 
Lung cancer 
Pancreatic cancer 
Cholangiocarcinoma 
Colorectal cancer 
Colorectal cancer 
Breast cancer 
Kidney cancer 
Pancreatic cancer 
Kidney cancer 
Glioblastoma 
Lung cancer 
Ovarian cancer 
Pancreatic cancer 
Colorectal cancer 
Breast cancer 
Prostate cancer 
Breast cancer 
No clinical benefit was found 
Reduce cancer risk 
Reduce cancer risk 
Reduce cancer risk, improve survival 
Reduce cancer risk 
Reduce cancer risk 
Reduce cancer risk 
Reduce cancer risk and mortality 
Reduce cancer risk 
No effect on cancer survival 
Reduced cancer aggressiveness 
Reduce cancer mortality 
No effect on cancer risk 
Improve overall survival 
No effect on cancer risk 
No effect on overall survival 
Improve overall survival 
Reduce cancer mortality 
Reduce cancer risk and mortality 
Reduce cancer risk 
Improve disease-specific survival 
Reduce cancer risk 
No effect on cancer risk 
Improve disease-specific survival 
Reduce cancer risk and mortality 
Improve median survival 
Reduce cancer risk 
No effect on cancer survival. 
Improve cancer survival 
Reduce cancer mortality 
No effect on cancer survival 
Reduce cancer risk 
Improve cancer survival 
Improve cancer-specific survival  
Reduce cancer risk 
No effect on cancer risk 
No effect on cancer risk 
Improve cancer survival 
Reduce cancer risk and mortality 
Reduce cancer risk 
Reduce cancer mortality 
[139] 
[137] 
[120] 
[121] 
[122] 
[123] 
[140] 
[124] 
[125] 
[138] 
[126] 
[141] 
[142] 
[143] 
[144] 
[145] 
[146] 
[147] 
[148] 
[149] 
[150] 
[151] 
[152] 
[153] 
[154] 
[155] 
[156] 
[157] 
[158] 
[159] 
[160] 
[161] 
[162] 
[163] 
[164] 
[165] 
[166] 
[167] 
[168] 
[169] 
[170] 
  24 
2.5.4 Signaling by statins 
The mevalonate pathway is also known as isoprenoid pathway, in which inhibition of 
HMG-CoA is a rate-limiting step. Isoprenoid is one of several products of the 
mevalonate pathway, which plays important role for various cellular functions. The 
inhibition of HMG-CoA by statins leads to reduce mevalonate levels and its 
downstream products, which in turn disturbs crucial cell functions including protein 
synthesis, cell signaling, cell cycle progression and membrane integrity. Therefore, 
tumor initiation, growth and metastasis might be inhibited by the effects of statins on 
these processes and subsequently on cancer cells (Figure 8) [171]. 
 
Figure 8: Pleiotropic effects of statins 
Farnesyl pyrophosphate (FPP); geranylgeranyl pyrophosphate (GGPP); p21WAF1/CIP1 and p27KIP1, 
two cyclin-dependent kinase inhibitors; c-jun NH2-terminal kinase (JNK9); MC, mitochondria; MMP-
9, matrix metalloproteinase-9 (MMP-9); nuclear factor κB (NF-κB) (Adapted from Ref. [171]). 
2.5.5 Effect of simvastatin in pancreatic cancer 
A recent study has precisely demonstrated that lipid metabolic pathways are 
disturbed in PDA and pancreatic cancer cells are highly dependent on cholesterol 
uptake [101]. A previous study suggested that simvastatin has a potential role for 
simvastatin-induced accumulation of cytosolic lipid droplets and upregulated genes 
involved in lipid metabolism in pancreatic cancer cells [172]. Notably, simvastatin 
showed stronger antitumor effects compared with other statins in several cancer cell 
lines in vitro [129, 173]. It has been also shown to significantly delay the progression 
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of PanIN lesions to PDA as well as to inhibit PDA growth in K-Ras mutant mice 
[135].  
2.6 Aim of the study 
According to the CSC theory solely the small subset of CSCs is held to be 
responsible for self-renewal, invasion, and metastasis. Recent clinical and 
epidemiological investigations demonstrate that daily intake of simvastatin not only 
reduces the risk of pancreatic cancer [121], but also inhibits metastasis and prolongs 
life of patients treated with simvastatin after diagnosed with prostate cancer [126], 
lung cancer [154] and renal cell carcinoma [143]. Aberrant activation of Shh 
signaling has been found in several types of cancer, including colon, breast, and 
pancreatic cancer. Moreover, Shh signaling plays an important role in carcinogenesis, 
differentiation, metastasis and resistance of chemotherapy and radiotherapy, 
indicating Shh pathway may be an intriguing therapeutic target focusing on 
pancreatic CSCs. The hypothesis of this project is that simvastatin targets 
pancreatic CSCs by inhibiting of Shh signaling. The aim of this project is to 
elucidate the effect of simvastatin to pancreatic CSCs with focus to self-renewal, 
metastasis, differentiation and chemotherapy resistance, and the underlying 
mechanisms. I studied the hypothesis of my thesis 1) at the cellular level in vitro, 2) 
in xenografts on fertilized chicken eggs in vivo and 3) in human samples from well-
characterized PDA patients ex vivo.  
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3. MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Equipment 
96 well plates (Cell star)  Greiner bio-one, Frickenhausen 
Accu-jet pro Brand, Wertheim 
Analytical balance (Mettler P220) Mettler Toledo, Gießen 
BioStation IM-Q Nikon, Düsseldorf 
Blotting chamber Starlab, Ahrensburg 
Cell counter–ZTM Series Beckman Coulter, Indianapolis 
Centrifuge–Capsulefuge PMC-060 Tomy, Fremont 
Centrifuge–Varifuge 3.0R Herraeus, Hanau 
Cyrostat (CM 3050) Leica, Wetzlar 
DNA/RNA UV–cleaner box Biosan, Riga 
Electrophoresis power supply Biotec Fischer, Reiskirchen 
Electrophoresis unit Bio-Rad, Munich 
Fluorescence microscope Leica, Wetzlar 
Fluorometer MS Laborgeräte 
FLUOstar OPTIMA BMG Labtech, Ortenberg 
Ice machine (AF80) Scotsman, Herborn 
Incubator-Digital motor breeders  Siepmann, Herdecke 
Inverted microscope–Eclipse TS100 Nikon, Düsseldorf 
Lab frezeers (-20oC, -80oC)  Liebherr, Ludwigshafen 
Laminar Flow Hood, HERA safe Herraeus, Hanau 
Light microscope Leica, Wetzlar 
Magnetic stirring hot plate Heidolph, Schwabach 
Micro Centrifuge–Biofuge 15R Herraeus, Hanau 
Mini Protean tetra system Bio-rad, Munich 
NanoDrop® Spectrophotometer NanoDrop Tech, Wilmington 
Neubauer hemacytometer Brand, Wertheim 
Odyssey® cLx imager Li-cor®, Lincoln 
pH-meter (pH 538) WTW, Weilheim 
Repeat pipettor, multistep Eppendorf, Hamburg 
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Shaker–Unimax 2010 Heidolph, Schwabach 
Spectrophotometer–Smart Spec 3000 Biorad, Munich 
SPOT™ FLEX 15.2 64MP camera Diagnostic Instruments, MI 
Step OneTM Real Time PCR system Applied Biosystems, Nidderau 
Thermal cyclers–C1000TM Bio-rad, Munich 
Thermomixer Eppendorf, Hamburg 
Ultracentrifuge–L8-M Beckman, Munich 
Vortexer–REAX 2000 Heidolph, Schwabach 
Water bath Kottermann, Hänsingen 
Xcell IITM Blot module Life Technologies, Nidderau 
3.1.2 Consumables 
6, 12, 24, 48 and 96 well plates Greiner, Frickenhausen 
96 well white polystyrene plates Sigma-Aldrich, Taufkirchen 
96 well black polystyrene plates Sigma-Aldrich, Taufkirchen 
Cell culture dishes TPP, Trasadingen 
Cell culture flasks TPP, Trasadingen 
Cell culture plates Nunc, Wiesbaden 
Cell scraper Greiner, Frickenhausen 
Centrifuge tubes TPP, Trasadingen 
Chamber slides Lab-Tek®, Naperville 
Coverslips Knittelgläser, Braunschweig 
Cryotubes Nunc, Wiesbaden 
Dispenser tips Nerbe, Winse 
Disposable scalpels Braun, Melsungen 
Eppendorf tubes Eppendorf 
Eggs, fertilized, chicken  Geflügelzucht Hockenberger, 
Eppingen, Germany  
Hemacytometer glasses Fischer Scientific, Nidderau 
Immobilon® transfer membrane Millipore, Billerica 
Microscope slides Menzel, Braunschweig 
Nitrocellulose membrane Amersham, Piscataway 
Parafilm M Pechiney, Chicago 
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Pasteur pipettes WTW, Weilheim 
Pipette barrier tips Starlab, Ahrensburg 
Polypropylene tubes Greiner, Frickenhausen 
Sterile filters Nalgene, Hamburg 
Sterile Gloves Hartmann, Heidenheim 
Syringe Hamilton, Bonaduz 
ThermanoxTM coverslips Thermo Scientific, Schwerte 
Tissue culture dishes Greiner, Frickenhausen 
Transwell® permeable support Corning Inc., Acton 
Weighing dishes Neolab, Heidelberg 
3.1.3 Media, supplements and reagents 
Advanced DMEM/F12 Invitrogen, Karlsruhe 
B27 supplement (50×) Invitrogen, Karlsruhe 
bFGF Pepro Tech, Hamburg 
Cell dissociation solution Sigma-Aldrich, Taufkirchen  
Dimethylsulfoxide (DMSO, >99%) Applichem, Darmstadt 
DMEM High Glucose Thermo Scientific, Rochester 
DNase/RNase free water Sigma-Aldrich, St. Louis 
Epidermal Growth Factor (rEGF) R&D Systems, Wiesbaden 
FCS Sigma, Deisenhofen 
Glutamax Thermo Fischer, Waltham 
HEPES PAA, Cölbe 
HEPES Buffer Solution PAA, Posching 
Human GAPDH primer Qiagen, Hilden 
Human Shh primer Thermo Scientific, Rochester 
Human Shh (GFP-tagged) plasmid  OriGene 
Human Smo Primer Thermo Scientific, Rochester 
Insulin Sigma-Aldrich, St. Louis 
Lipofectamine 2000 Invitrogen, Dreieich 
Lipofectamine RNAiMAX Invitrogen, Dreieich 
Matrigel BD Biosciences, Heidelberg 
OptiMEM® Invitrogen, Karlsruhe 
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Shh siRNA Silencer® Thermo Scientific, Rochester 
SilencerTM Negative control No. 1 siRNA Thermo Scientific, Rochester 
Trypan blue Biozol, Eching 
Trypsin-EDTA PAA, Cölbe 
Water–Aqua ad injectabilia Braun, Melsungen 
3.1.4 Chemicals 
Acetone Sigma-Aldrich, St. Louis 
AEC single solution StemCell Tech., Köln 
Alcian blue staining solution Sigma-Aldrich, St. Louis 
Avidin/Biotin Blocking Kit Linaris, Werheim-Bettingen 
Bovine Serum Albumin (BSA) New England Biolabs, Frankfurt 
DAPI Sigma-Aldrich, Taufkirchen  
EDTA Sigma-Aldrich, St. Louis 
Ethanol Sigma-Aldrich, St. Louis 
Fast BCIP/NBT tablet Sigma-Aldrich, St. Louis 
Fluoromount G Biozol, Eching 
Formalin Carl Roth, Karlsruhe 
Goat serum Alexis, Grünberg 
Isopropanol Carl Roth, Karlsruhe 
Milk powder Carl Roth, Karlsruhe 
MTT Invitrogen, Karlsruhe 
Narcoren® IBF, Heidelberg 
Oil Red O staining solution Sigma-Aldrich, St. Louis 
Paraformaldehyde (37%) Merck, Darmstadt 
PBS Sigma-Aldrich, St. Louis 
PMSF Carl Roth, Karlsruhe 
Primers Biocat, Heidelberg 
Protease inhibitor cocktail tablets Roche, Mannheim 
Protein ladder-PageRulerTM Fermentas, St. Leon-Rot 
SDS pellets Carl Roth, Karlsruhe 
Simvastatin Merck, Darmstadt 
Sodium chloride Carl Roth, Karlsruhe 
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Sodium citrate Fischer, Schwerte 
Sodium hydroxide Carl Roth, Karlsruhe 
TEMED Merck, Darmstadt 
Tris Merck, Darmstadt 
Tween-20 Sigma-Aldrich, St. Louis 
3.1.5 Kits 
Avidin Biotin Blocking Kit Linaris, Wertheim-Bettingen 
BCATM protein assay kit Thermo Fischer, Rockford 
DNeasy® blood and tissue kit Qiagen, Hilden 
E.Z.N.A.® Tissue DNA kit Omega Bio-tek, Norcross, USA 
GeneChip® WT Plus Reagent kit Affymetrix, Santa Clara, USA 
GeneChip® Hybridization, Wash and Stain 
Kit 
Affymetrix, Santa Clara, USA 
 
High Capacity RNA-to-cDNA Kit Thermo Fischer, Rockford 
Plasmid mini and maxi preparation kits Invitrogen, Karlsruhe 
Proteinase K Invitrogen, Karlsruhe 
QIAquick® Gel Extract Kit Qiagen, Hilden 
RealTime-Glo™ MT Cell Viability Assay Promega, Mannheim 
RNeasy kit Qiagen, Hilden 
Site-Directed Mutagenesis Kit Agilent, Santa Clara 
Taqman®2× Universal PCR Master Mix, 
No AmpErase® UNG 
Thermo Fischer, Rockford 
Taqman® Endogenous Controls Thermo Fischer, Rockford 
TaqMan® Gene Expression Assay Thermo Fischer, Rockford 
Taqman® Reverse Transcription kit Thermo Fischer, Rockford 
3.1.6 Buffers and solutions 
All buffers were prepared in distilled water unless otherwise specified. 
10× Phosphate Buffered Saline (PBS) 
solution 
 2 g KCl 
 2 g KH2PO4 
 14.41 g Na2HPO4×2H2O 
 80 g NaCl 
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 Made up to 1 L with ddH2O  
 pH 7.4 
1.5 M Tris-HCl 36.32 g Tris 
200 mL ddH2O 
pH 8.8 
10% Sodium Dodecyl Sulfate (SDS) 10 g SDS 
100 mL ddH2O 
10× Triethanolamine Buffered Saline (TBS) 
solution 
87.6 g NaCl (1.5 M) 
12.1 g Tris (100 mM) 
1 g NaN3 
Made up to 1 L with ddH2O 
pH 7.5 
10× Western Blot Running buffer 144 g Glycine (1.92 M) 
10 g SDS (1%) 
30 g Tris (0.25 M) 
Made up to 1 L with ddH2O 
pH 8.3 
1 M Tris-HCl 24.2 g Tris 
200 mL ddH2O 
pH 6.8 
4× lämmli buffer 1 mL β-mercaptoethanol 
0.8g 8% SDS 
4 mL 40% glycerol 
2 mL 200 mM Tris-HCl (pH 6.8) 
Bromophenol blue 
Made up to 10 mL with ddH2O 
Chicken saline 7.2 g NaCl 
0.37 g KCl 
0.23 g CaCl2 
Made up to 1 L with ddH2O 
LB media 10 mg/mL Bacto-tryptone 5 mg/ml 
yeast extract 
10 mg/ml NaCl 
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2% w/v dextrose (pH 7.4) 
LB/amp/X-Gal plates LB media 
15 g/l agar 
75 µg/mL ampicillin  
100 µg/mL X-Gal 
Membrane Extraction (ME) buffer 30 mM Tris 
150 mM NaCl 
0.5% Triton X-100 
0.5% Na-Desoxycholate 
1 µL/mL 1 M DTT 
10 µL/mL 100 mM PMSF 
1 µL/mL aproptinin (1 mg/mL) 
Transfer buffer 2.930 g glycine (39 nM) 
5.810 g Tris (48 mM) 
0.375 g SDS (0.0375% w/v) 
200 mL methanol (20%) 
Made up to 1 L with ddH2O 
Tumorsphere medium Advance DMEM/F12 medium 
B27 supplement (50×) 
20 ng/mL rEGF 
20 ng/mL bFGF 
5 µg/mL insulin 
5 mL Glutamax 
3.1.7 Antibodies 
Primary antibodies 
Anti-Shh, rabbit, polyclonal Abcam, Cambridge 
Anti-smoothed, rabbit, polyclonal Abcam, Cambridge 
Anti-Sufu, rabbit, monoclonal Abcam, Cambridge 
Anti-Ki67 Abcam, Cambridge 
Anti-BMP4, rabbit, polyclonal Abcam, Cambridge 
Anti-Gli, mouse monoclonal Cell Signaling, USA 
Anti-Vimentin, mouse monoclonal Abcam, Cambridge 
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Anti-CXCR4, rabbit polyclonal Abcam, Cambridge 
Anti-cMet, rabbit monoclonal Cell Signaling, USA 
Anti-β-actin, mouse monoclonal  Sigma-Aldrich, St. Louis 
Secondary antibodies 
Anti-mouse-IgG, IRDye® 800CW 
Infrared Dye (Goat, anti-Mouse IgG, 
western blot dilution 1:5000)  
LI-COR Biosciences GmbH, 
Bad Homburg, Germany  
 
Anti-mouse-IgG, IRDye® 680RD 
Infrared Dye (Goat, anti-Mouse IgG, 
western blot dilution 1:5000)  
LI-COR Biosciences GmbH, Bad 
Homburg, Germany  
 
Anti-rabbit-IgG, IRDye® 680RD 
Infrared Dye (Goat, anti-Mouse IgG, 
western blot dilution 1:5000)  
LI-COR Biosciences GmbH, Bad 
Homburg, Germany  
 
Anti-rabbit-IgG, IRDye® 800CW 
Infrared Dye (Goat, anti-Mouse IgG, 
western blot dilution 1:5000)  
LI-COR Biosciences GmbH, Bad 
Homburg, Germany  
 
Anti-mouse-IgG, AlexaFluor 488 BD Pharmingen, Heidelberg 
Anti-mouse-IgG, AlexaFluor 594 Molecular probes, Karlsruhe 
Anti-rabbit-IgG, AlexaFluor 488 Molecular probes, Karlsruhe 
Anti-rabbit-IgG, AlexaFluor 594 Molecular probes, Karlsruhe 
3.1.8 Cell culture 
The normal pancreatic duct fibroblast (CRL-4023), non-malignant human primary 
mesenchymal stromal cells (MSC) cell lines and the established human pancreatic 
cancer cell line BxPc-3，MIA-PaCa2, PANC1 were obtained from ATCC [174-177]. 
The primary cell line ASAN-PaCa was established and provided by N. Giese from 
European pancreas center [178]. Negative mycoplasma cultures were confirmed by 
monthly mycoplasma test. 
3.1.9 Patient tissue 
Surgical specimens were obtained from patients admitted to the Department of 
General, Visceral and Transplantation Surgery. The study was approved by the 
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ethical committee of the University of Heidelberg after receiving written informed 
consent from the patients. Clinical diagnoses were established by conventional 
clinical and histological criteria. All surgical resections were indicated by principles 
and practice of oncological therapy.  
3.1.10 Preparation of stock solutions 
Gemcitabine was purchased from the Pharmacy of the University Hospital 
Heidelberg supplied by Eli Lilly Company, with a concentration of 38 mg/ml. 
Gemcitabine stored at 4°C was freshly diluting aliquoted 100 µM stock in DMEM. 
According to average weight of chick embryo on embryonic development day (EDD) 
15 and concentration for mouse model recently described [179], stock was diluted in 
chick saline to final concentration of 10 µM for intravascular injection. Simvastatin 
(≥95%) was bought from Merck and dissolved in ddH2O (PH 7.0) with a stock 
concentration of 10 mM. The stock was divided into aliquots and stored in -20°C and 
were freshly diluted in culture medium to reach different concentrations according to 
the experiments purpose. Each stock was used only once immediately after thawing.  
3.2 Methods 
3.2.1 Cell culture 
3.2.1.1 General cell culture 
Cells were cultured in an incubator at 37°C, 5% CO2. Media were supplemented, if 
not indicated differently, with 10% [v/v] FCS, 2 mM L-Glutamin, 10 mM HEPES 
(pH 7.4) and 2.5 µg/mL of Plasmocin. Media were pre-warmed at 37°C prior use. 
FCS was heat-inactivated for 30 min at 56°C. For determination of the number of 
viable cells, cell suspension was diluted 1:1 in Trypan blue solution (0.125%). Cells 
were counted using a Cell counter-ZTM Series as recommended by the supplier. 
3.2.1.2 Passaging of cells 
When cells were 80-90% confluent in flasks, media were aspirated and cells were 
gently washed once with 5 mL 1× PBS. After aspirating PBS, 2 mL or 1 ml 1× 
Trypsin-EDTA was added to per T-150 flask and cells were incubated at 37°C and 5% 
CO2 until more than 90% cells were observed detached from the flask. Trypsin was 
inactivated by 10 mL medium. Suspended cells were put in a 15 mL tube, and then 
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centrifuged at 1500 rpm for 5 min. The supernatant was removed and cells were 
resuspended with normal culture medium. After determination of the number of cells, 
cells were passaged as required ratio. 
3.2.1.3 Thawing of cells 
The cryotubes were put in the warm water bath at 37°C until a little piece of ice clot 
was still visible in the cryotube. Cell suspension was transferred to 10 mL of pre-
warmed medium and centrifuged at 1500 rpm for 5 min. After removing supernatant, 
cells were carefully resuspended in appropriated fresh cell culture medium and 
transferred to a culture flask. In order to completely eradicate the toxicity of remained 
DMSO to cells, medium was normally changed after 24 h. 
3.2.1.4 Freezing of cells 
Cells in flasks were trypsinized after washed once with 5 mL 1× PBS. After 
quenched trypsin reaction with media, resuspended cells were centrifuged at 1500 
rpm for 5 min, and then removed supernatant. Aliquots of 3×106 to 1×107 cells were 
well resuspended in 900 µL corresponding media with 10% FCS and 100 µL sterile 
DMSO in each labeled cryotube. Cryotubes were immediately put in an isopropanol-
filled cryo-container to get a constant decrease in the temperature at a rate of 
1 °C/min. Subsequently, cryotubes were transferred to the -80°C freezer. 24 h later 
cryotubes were transported to a freezer with a temperature of -140°C for long-term 
storage. 
3.2.1.5 Preparation of chick eggs and transplantation of established cell lines 
Fertilized eggs from highly genetically identical hybrid Lohman Brown (LB) chicks 
were obtained from a local ecological hatchery. All eggs are specific pathogen free 
animals and tested against infectious bronchitis, leucosis and mycoplasma. On EDD1, 
eggs were incubated in 37.8°C at a humidity of 45-55% in digital motor breeders 
Type 168/D. On EDD 4.5 ml of albumen was absorbed removed with a syringe, thus 
allowing detachment of the embryo. Afterward, a small window was cut into the 
eggshell, and the window was wrapped with tape. On EDD 9 small handmade rings 
from Thermanox™ coverslips were deposited on the chorioallantoic membrane 
(CAM), followed by adding 5×105 of MIA-PaCa2 cells in matrigel into the rings. For 
treatment, diluted gemcitabine, simvastatin or combination were intravenously 
injected in blood vessels of the CAM on EDD 12 and 15 respectively. Tumor growth 
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and tumor take rate were evaluated at EDD 18. All embryos that died before EDD 18 
were excluded from further analyses. Tumor volumes were determined after resection 
of tumor xenografts by the following formula: Volum=4/3×π×r3 (r=1/2×square root 
of diameter 1×diameter 2) [180]. Tumor take rate was calculated by the following 
method: N1×100/N2 (N1=number of embryos with tumor; N2=number of live 
embryos). Tumor tissue was kept frozen in dry ice and embedded in Tissue Tek 
O.C.T. compound for further analyses. 
3.2.2 MTT assay 
Measurement of cell viability and proliferation was detected by the MTT assay. Cells 
were seeded in 96-well flat bottom plates at a density of 3-5×104/mL, 100 µL per 
well. 24 h later cells were treated with corresponding drugs or transfected with 
siRNA or plasmid for different time points. At the end of each treatment time point, 
10 µL of MTT stock solution (12 mM in PBS) per well was added. Subsequently, the 
96-well plates were incubated for 4 h in an incubator at 37°C. After completely 
removing media, 200 µL pre-warmed DMSO was added. The plate was shaken in a 
shaker until all of the blue crystals were completely solubilized. Subsequently, the 
optical density of each well was detected at 560 nm with an ELISA reader. 
3.2.3 Spheroid and colony formation assay 
3.2.3.1 Spheroid formation assay 
Cancer cells were cultured in human NeuroCult NS-A basal serum-free medium 
supplemented with 2 µg/mL Heparin, 20 ng/mL hEGF, 10 ng/mL hFGF-b and 
NeuroCult NS-A Proliferation Supplements. Low densities of cells (1.5×103 cells/mL) 
were seeded in 24-well ultra-low adhesion plates for spheroid formation, 1 mL per 
well. 24 h later cells were treated with simvastatin, gemcitabine or both agents 
together and incubated for 3 days. Then spheroids were photographed at day 5 and 
the percentage of cell spheroids was calculated. To evaluate potential for the 
secondary spheroids formation, equal numbers of cells were reseeded. Same manner 
of spheroid formation was quantified [181]. 
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3.2.3.1 Colony formation assay 
Briefly, cells were collected as described above and seeded in 6-well plates 
containing 1.0-2.0×105 cells/well, followed by treatment with different drugs or 
siRNA for 72 h. Subsequently, cells were collected again and re-plated at a density of 
500-2000 cells per well in 6-well plates triplicates. After incubation for two weeks in 
incubator without changing medium, cells were fixed with 2 mL 3.7% 
paraformaldehyde (PFA) for 10 min followed by 2 mL 70% ethanol for another 10 
min after wash once with 1× PBS. Then cells washed 3 times with water and stained 
with 0.05% Coomassie blue for 5 min. Subsequently, cells were washed with water 
and dried overnight. A colony was defined as a spot comprising more than 50 cells. 
The number of colonies was quantified under a dissecting microscope. The 
percentage of plating efficiency was calculated (plating efficiency of non-treated 
cultures=1) [176, 181]. To investigate potential for formation of the secondary 
colonies, cells were collected from the colonies above and equal numbers of cells 
were reseeded, colonies were calculated in the same manner. 
3.2.4 Evaluation of differentiation potential  
3.2.4.1 Evaluation of osteoblast differentiation 
Cells were seeded at a density of 0.8-1.2×105 cells/well in a 6-well plate, 3 mL 
medium per well, and were treated with simvastatin for 72 h and the media were 
changed with 2 mL osteogenic differentiation media. The cells were grown for 10 
days, with medium replacement triple a week. Osteogenic differentiation was 
measured by staining with SIGMAFASTTM BCIP®/NBT substrate according to the 
manufacturer’s instructions. Images of staining cells were taken using a NikonEclipse 
TS100 microscope (200× magnification). 
3.2.4.2 Evaluation of adipocyte differentiation 
0.8-1.2×105 cells were seeded in a 6-well plate. After reaching 80-90% confluence, 
the cells were treated with simvastatin for 72 h and incubate in adipogenic 
differentiation medium for 12 days with changing the medium every 3 days. Cells 
were gently washed with PBS, fixed with methanol for 5-10 min and incubated in Oil 
Red O for 30 min at room temperature. Then the cells were washed with distilled 
water. Red staining cells were visualized using a Nikon Eclipse TS100 microscope. 
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3.2.5 Protein extraction and western blot analysis 
3.2.5.1 Protein extraction 
1.0-2.0×106 cells were seeded in 10 cm tissue culture plates and treated cells at and 
treated for 72 h. The protein samples were stayed on ice during the entire procedure 
to avoid degradation. All of cells were harvested by scraping and put into 15 mL 
tubes and then centrifuged at 1500 rpm for 5 min at 4°C. The pellet was resuspended 
in 1.0 mL cool 1× PBS and transferred into a 1.5 mL eppendorf tube. The samples 
were centrifuged at 2000 rpm for 5 min at 4°C and the supernatant was removed. The 
pellet was resuspended in 5× ME buffer containing complete protease inhibitor 
according to the pellet volume (ME buffer volume: pellet volume=4-5:1) and 
incubated on ice for 10 min after mix. After that, samples were centrifuged at 14,000 
rpm for 20 min and then supernatant was transferred to a new 1.5 mL tube for 
determination of protein concentration. Subsequently, protein solutions were used for 
SDS-gel electrophoresis or were stored at -20°C.  
3.2.5.2 Detection of protein concentration 
For detection of total protein concentration, the Pierce BCA Protein Assay was used. 
Briefly, 5 µL of each standard and sample replicate are pipetted into each 
corresponding microplate well of a 96 well plate and then 200 µL of the working 
reagent (Kit BCA reagent A: B=50:1) were added to each well and incubated for 30 
min at 37°C. After that, an ELISA-Reader well determined absorption in each. To 
determine the protein concentration of each unknown sample, a standard curve was 
prepared by plotting the absorption of each standard versus its concentration (µg/mL) 
and calculated the concentration of each detected samples according to the 
manufacturer’s instructions.  
3.2.5.3 SDS-polyacrylamid gel electrophoresis (SDS-PAGE) 
Denatured proteins can be separated by polyacrylamid gel electrophoresis (PAGE) 
according to their molecular weight. The proteins are denatured and become 
negatively charged by SDS. The charge of the protein-SDS-complex is proportional 
to protein size and thus migration velocity through the gel is dependent on molecular 
weight. The SDS-gel consists of separating gel and stacking gel and the concentration 
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of the SDS-gel depends on the molecular weight of the desired protein (Table 5, 
Table 6).  
Table 5: Composition of separation gel (10 ml) 
Complements 6% 8% 10% 12% 15% 
Protogel 
1.5M Tris pH 8.8 
10% SDS 
Water 
Glycerol 
10% APS 
TEMED 
2.0 mL 
2.5 mL 
100 µL 
4.79 mL 
500 µL 
100 µL 
10 µL 
2.67 mL 
2.5 mL 
100 µL 
4.32 mL 
500 µL 
100 µL 
10 µL 
3.33 mL 
2.5 mL 
100 µL 
3.46 mL 
500 µL 
100 µL 
10 µL 
4.0 mL 
2.5 mL 
100 µL 
2.8 mL 
500 µL 
100 µL 
10 µL 
5.0 mL 
2.5 mL 
100 µL 
1.8 mL 
500 µL 
100 µL 
10 µL 
 
Table 6: Composition of stacking gel (4 ml) 
  Components 4% gel 
  Protogel 
  1.M Tris pH 6.8 
  10% SDS 
  Water 
  10% APS 
  TEMED 
520 µL 
500 µL 
40 µL 
2.89 mL 
40 µL 
4 µL 
After polymerization, gels were fixed in a gel chamber containing 1× running buffer. 
Protein solutions were diluted 1:3 with 4× loading buffer and boiled for 3 min at 
99 °C to accelerate denaturation and binding of SDS to the proteins. The Loading 
buffer contains β-Mercaptoethanol, which can break disulphide bridges denatured 
proteins (polypeptides) become surrounded by negatively charged SDS-molecule 
micelles and migrate to the anode. Subsequently, cooked samples were incubated on 
ice for 5 min. After gel wells were rinsed several times by syringe to completely 
exclude the pieces of gels in wells, gels were loaded with 25-50 µg proteins and 
protein separation was performed at 80 V for 20 min followed by separation at 160 V. 
A prestained protein ladder was used as a marker for determination of protein size. 
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3.2.5.4 Electroblot 
After electrophoresis, gels with separation proteins were electroblotted on a nitro-
cellulose membrane. The membrane was activated in 100% methanol for 15 s and 
rinsed under running water before use and then pre-soaked in transfer buffer for at 
least 10 min. Filter papers were also pre-soaked in transfer buffer before use. Three 
filter papers were placed on the bottom of the chamber followed orderly by the 
nitrocellulose membrane, gel, and another three filter papers. Then, the chamber was 
closed and the time and amperage of transfer were set based on the instructions of the 
manufacturer and the protein size. 
3.2.5.5 Detection of proteins 
To detect the proteins on the membranes, membranes were placed upside down in a 
blockholder and blocked for 3 min with 0.1% [w/v] milk powder in 0.1% TBS-
Tweenat room temperature using a Millipore Snap ID. Subsequently, blocking 
solution was aspirated and membranes were incubated for 10 min at room 
temperature with 2 mL primary antibodies diluted in TBS-Tween (1:1000). After that, 
membranes were washed 3 times with 15 mL TBS-Tween and then incubated for 
another 30 min at room temperature with 2 mL secondary Infrared Dye conjugated 
second antibody diluted in TBS-Tween (1:5000). Then, membranes were washed 
with additional three times and put immediately onto the Odyssey® CLx Infrared 
Imaging System. Protein bands were measured and calculated with the correspond 
software. 
3.2.6 Immunohistochemistry 
Frozen slides (fixed with 4% PFA) were rehydrated in 1× TBS for 5 min and blocked 
with a blocking solution containing 20% goat serum and 4 drops/mL of avidin 
solution in 1× PBS with 0.2% Tween for 30 min. After blocking solution was 
removed, samples were incubated with 100 µl primary antibody solution in which 
primary antibody was diluted in 1× PBST including 4% goat serum and 4 drops/mL 
biotin solution (dilution 1:50 to 1:200) overnight at 4°C. At one slide of each group, 
omission of primary antibody was used as a negative control. After an overnight 
incubation, samples were washed twice in 1× PBS with 0.2% Tween for 5 min and 
once in 1× PBS for 5 min. Then, endogenous peroxidase was quenched by 3% 
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hydrogen peroxide in methanol for 10 min. Secondary antibody was diluted 1:200 in 
1× PBS with 4% goat serum and 100 µl of secondary antibody solution was added to 
samples followed an incubation for 30 min at room temperature. Subsequently, 
samples were washed 2 times in 1× PBS with 0.2% Tween for 5 min and 1 time in 1× 
PBS for 5 min. After that, 100 µl ABC solutions (2.5 mL PBS + 1 drop avidin + 1 
drop biotin) were pipetted to each sample and incubated for 30 min. After washing in 
1× PBS 3 times for 5 min, AEC was added to each sample and incubated for 3-10 
min until the color reaction was observed under the microscope and stopped when 
cells became brown or red. The reaction was stopped by washing with 1× PBS three 
times for 5 min. Subsequently, samples were counterstained for three min in 
haematoxylin followed by washing in tap water and distilled water (3×5 min). Finally, 
the samples were mounted in xylene and random regions of interest were chosen with 
the Leica DMRB microscope. 
3.2.7 Immunofluorescence 
Frozen tissue sections were fixed with 4% PFA for 10 min and were washed in 1× 
TBS for 5 min. Then samples were incubated with a blocking solution containing 20% 
goat serum in 1× PBS with 0.2% Tween for 30 min at room temperature to inhibit 
unspecific antibody binding. Subsequently, samples were incubated with 100 µl 
primary antibody solution in which primary antibody was diluted in 1× PBST 
including 4% goat serum overnight at 4°C, with omission of primary antibody served 
as a negative control. Then, samples were washed twice in 1× PBS with 0.2% Tween 
for 5 min and once in 1× PBS for 5 min and then incubated with Alexa Fluor 488-
conjugated secondary antibody for 30 min in the dark. After being washed as 
described above, samples were incubated with 100 µl second primary antibody 
solution in which primary antibody was diluted in 1× PBST including 4% goat serum 
and nuclei were counterstained with DAPI (dilution 1:100). The DAPI containing 
solution centrifuged for 30 min at 14000 rpm before usage. Samples were washed as 
described above and then incubated with Alexa Fluor 594-conjugated for 30 min. 
After that, the samples were washed with 1× PBS once and dH2O twice for 5 min. 
Finally, the samples were mounted with Fluoromount G and stored at -20°C in the 
dark. Randomly chosen fields were examined at 400× magnification using a Leica 
DMRB microscope. Images were captured using a SPOTTM FLEX 15.2 64Mp 
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shifting pixel digital color camera and analyzed with SPOT Basic/Advanced 4.6 
software. The percentage of double-positive cells was calculated. 
3.2.8 Haematoxylin and Eosin (H&E) Staining 
Frozen tissue sections were fixed with 4% PFA for 10 min and were washed in 1× 
TBS for 5 min. Subsequently, samples were counterstained for 3-5 min in 
haematoxylin followed by washing in tap water until to get perfect blue nuclear 
staining. After that, samples were stained with Eosine for 3-5 min and then washed 
once with H2O. Subsequently, samples were dipped in ethanol 70%, ethanol 80%, 
ethanol 90%, and ethanol 100% in sequence for 5 min, respectively, and held in 
xylene twice for 3 min. After dried completely, the samples were mounted and 
randomly fields were chosen with the Leica DMRB microscope.  
3.2.9 Transplantation of tumor cells to fertilized chicken eggs 
The chorioallantoic membrane (CAM) assay is an animal substitute model for 
cultivation of human tumors. 15 to 20 fertilized eggs were used for each study group. 
On day 1, eggs were washed with 70% ethanol and incubated in a special incubator at 
37.8°C. On day 4, after 2-3 mL of albumen was removed with a syringe, a 2 cm 
diameter hole was penned on each egg using Leukosilk strips and curved scissors. 
The viability of the embryos was examined by observing a beating heart and clear 
blood vessels. Then, the holes on the eggs were covered with strips and put back in 
the incubator in a horizontal position. On day 8 of embryonic development, small 
handmade rings were placed on the CAM and 1× 106 cancer cells mixed in matrigel 
were seeded in the middle of the ring surrounded by clear blood vessels. Tumor cells 
were only transplanted to eggs with viable embryos. After that, the egg shell was 
taped with a strip and replaced in the incubator for additional 10 days. On day 18, the 
tumor-take was performed and all embryos that died before day 18 were excluded 
from further analyses. To evaluate the tumors, tumor volume was determined 
(diameter 1 and 2) and calculated using the following formula: Volume=4/3×π×r3 
(r=1/2×√ of diameter 1×diameter 2). Subsequently, the tumor tissues were fixed as 
soon as possible to achieve the best morphology for further investigations. 
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3.2.10 Isolation of genomic DNA and human Alu PCR amplification 
Tissue DNA was extracted from fresh tissue obtained from the CAM adjacent the 
plastic ring using the E.Z.N.A.® Tissue DNA kit according to the manufacturer’s 
instructions (Omega Bio-tek, Norcross, GA, USA). The PCR amplification was 
carried out with 0.5 µM of both forward and reverse primers using FastStart Taq 
DNA Polymerase, dNTPack according to the manufacturer’s instructions (Roche, 
Mannheim, Germany). The total reaction volume was 50 µl, including 5 µl of 
synthesized cDNA or 200 ng genomic DNA. The following primers were used: 
Human Alu-sense - 5’-GTAAGAGTTCCGTAACAGGACAGCT-3’; Alu-antisense -
5’-CCCCACCCTAGGAGAACTTCTCTTT-3’. Chicken GAPDH Alu DNA were 
Alu-sense, 5'-GAG GAA AGG TCG CCT GGT GGA TCG-3', and Alu-antisense, 5'-
GGT GAG GAC AAG CAG TGA GGA ACG-3'. The PCR conditions were 40 
amplification cycles of 60 s at 94°C, 120 s at 58°C, and 120 s at 72°C. PCR products 
were analyzed on a 2% agarose gel. 
3.2.11 RNA expression profiling and real time qualitative PCR  
3.2.11.1 mRNA isolation and mRNA concentration measurement 
Total RNA was isolated using the RNeasy Mini Kit from Qiagen and stored in -80°C 
or immediately used. One microliter of total mRNA was mounted onto NanoDrop 
2000 Spectrophotometer for measurement.  
3.2.11.2 mRNA expression profiling  
mRNA expression profiling was done by Center of Medical Research (ZMF) 
Mannheim. Briefly, 500 ng mRNA was checked by quality control and the 
concentration was measured again, then gene expression profiling was performed 
using human HuGene-2_0-st-type array from Affymetrix. Biotinylated antisense 
cRNA was then prepared based on standard Affymetrix protocol with the GeneChip® 
WT Plus Reagent Kit and the GeneChip® Hybridization, Wash and Stain Kit. 
thereafter the hybridization on the chip was performed on a GeneChip Hybridization 
oven 640 and dyed in the GeneChip Fluidics Station 450, then scanned with a 
GeneChip Scanner 3000.  
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3.2.11.3 mRNA expression analysis  
A Custom CDF Version 20 with ENTREZ based gene definitions was used to 
annotate the arrays [182]. The Raw fluorescence intensity values were normalized 
applying quantile normalization and RMA background correction. One-Way 
ANOVA was performed to identify differential expressed genes using a commercial 
software package SAS JMP10 Genomics, version 6, from SAS (SAS Institute, Cary, 
NC, USA). A false positive rate of a=0.05 with FDR correction was taken as the level 
of significance.  
Gene Set Enrichment Analysis (GSEA) was used to evaluate whether defined lists of 
genes exhibit a statistically significant bias in their distribution within a ranked gene 
list using the software GSEA [183]. Pathways of different cell functions were 
obtained from public external databases (KEGG, http://www.genome.jp/kegg). The 
heat map was created by R software with the package “gplot”.  
3.2.11.4 Reverse transcription of mRNA to cDNA 
mRNA was extracted as described above. A total of 1-100 ng mRNA was used for 
reverse transcription using the High Capacity RNA to c-DNA Kit. The reverse 
transcription reaction mix was prepared on ice according to Table 7. Then, the 
reverse transcription reaction was incubated for 60 min at 37°C and inactivated by 
heating to 95°C for 5 min and hold at 4°C. The cDNA was stocked in -80°C or 
diluted in 200 µL RNase-free water for immediate real-time PCR.  
 
Table 7: Reverse-transcription reaction components 
Component Volume 
2× RT (Reverse Transcription) Buffer 
20× RT Enzyme Mix 
Template RNA (50 ng) 
10 µL 
1 µL 
9 µL 
Total volume 20 uL 
3.2.11.5 Real time quantitative PCR 
Real time quantitative PCR was performed using Master mix without UNG. The 
reaction mix was prepared according to Table 8 and transferred to a 48-well plate.  
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Table 8: Reaction mix of Real Time PCR 
Component Volume 
Primer Mix  
2× TaqMAN Gene Expression Master Mix 
Rnase-free water  
Template cDNA  
1 µL 
10 µL 
5 µL 
4 µL 
Total volume 20 uL 
After the plate was tightly sealed with film, it was centrifuged for 3 min at 3000 g at 
room temperature to remove bubbles. Then the step one real time PCR was set up 
according to Table 9.  
Table 9: Cycling conditions for real-time PCR 
Step Time Temperature 
PCR initial activation step 
Denaturation 
Annealing 
Break  
Cycle number  
10 min 
15 s 
1 min 
∞ 
40 cycles 
95°C 
95°C	 
60°C 
4°C 
Human GAPDH from Qiagen was used as controls. The used primers were and Shh  
3.2.12 Isolation of plasmid DNA 
E.coli DH5α cells were used for plasmid cloning. Frozen DH5α cells were taken from 
the -80 °C freezer and thawed on ice for 5 min. 2 µg of plasmid DNA was added to 
25 µl thawed DH5α cells. Lysogeny broth (LB, 900 µl) medium without antibiotics 
was added to the cells-plasmid mixture. The mixture was incubated in a 37°C shaking 
incubator at 250 rpm overnight to allow bacterial growth. The next day, 50 µl of 
bacterial cells were plated on the LB/antibiotic agar plates. Sterile pipette tips were 
used to create single colonies by running streaks in LB agar plates, Plates were 
placed upside down in incubator overnight at 37°C. After transformation, a single 
colony of bacteria was picked and inoculated in 4 ml liquid LB medium with 
antibiotic (Ampicillin, 100 µg/ml) overnight in a 37°C shaking incubator. After 
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recovering plasmid, the level of plasmid DNA was evaluated using plasmid mini-
prep kit. 250 ml liquid LB medium mixed with 4 ml of prepared bacterial cells were 
inoculated overnight in a 37°C shaking incubator to amplify plasmid DNA for 
purification. DNA preparation was performed using a PureLink HiPure Plasmid 
Maxiprep Kit according to the manufacturer’s recommendations (Invitrogen). 
3.2.13 Transfection of siRNA and plasmid DNA 
3.2.13.1 Transient transfection of plasmid DNA 
For overexpression of Shh protein, cells were seeded on 6-well plates or 96-well 
plates in DMEM containing 10% FBS without antibiotics. After cells had been 
attached, human Shh plasmid was used for transfection with Lipofectamine 2000 
according to the instructions manufacturer. Briefly, 4 µg of Shh plasmid and 10 µL of 
Lipofectamine 2000 were incubated separately in 250 µL of Opti-MEM I Reduced 
Serum Medium (Invitrogen). After 5 min of incubation at room temperature, the 
diluted plasmids and Lipofectamine 2000 were combined and incubated for an 
additional 20 min at room temperature to allow the formation of transfection 
complexes and then transferred to corresponding wells. Usually, cells under the 
transfection complexes were incubated at 37°C in a CO2 incubator for 24 h, followed 
by changing with corresponding medium.  
 
Figure 9: Plasmid map of human Sonic hedgehog 
3.2.13.2 siRNA transient transfection 
For knockdown of Shh protein expression, pooled siRNA duplexes were used, 
negative control used non-targeting siRNA. Lipofectamine 2000 from Invitrogen was 
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used to transient siRNA transfection according to the instructions of manufacturer. 
Transfected cells were cultured for 72 h at 37°C in a CO2 incubator. 
3.3 Statistical analysis  
The IC50 doses and the combination index were calculated by the Chou-Talalay 
method [184, 185]. The data obtained in cell culture experiments are presented as 
mean ± SD for at least three independent experiments performed in triplicate. The 
statistical significance was evaluated by Student’s t-test if data were normally 
distributed and groups had equal variance, otherwise, Mann-Whitney test was used. 
P<0.05 was considered statistically significant. One star represents P<0.05 and two 
stars represent P<0.01.  
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4. RESULTS 
4.1 Simvastatin inhibits viability and enhances cytotoxicity of gemcitabine in 
PDA  
To get knowledge about the chemosensitivity of pancreatic cancer cells, 2 highly 
aggressive (MIA-PaCa2, PANC-1) and 2 less aggressive (ASAN-PaCa, BxPc-3) 
human established PDA cell lines were treated with gemcitabine and the cell viability 
was measured by MTT. It was found that the aggressiveness corresponded to 
gemcitabine sensitivity (ASAN-PaCa＜BxPc-3＜MIA-PaCa2＜PANC-1) (Figure 
10A). To evaluate the effect of simvastatin on proliferation，the cells were treated 
with simvastatin in concentrations found in plasma of patients, with typical plasma 
concentrations in the range of 1 nM to 2 mM [186, 187]. The results revealed the 
viability decreased in a time and dose dependent-manner especially after 48 h and 72 
h treatment with increasing simvastatin concentration (Figure 10B). From the 
obtained data, the IC50 doses of simvastatin and gemcitabine was calculated with the 
Chou-Talalay method (Table 10). 
Table 10: Simvastatin synergistically interacts with gemcitabine in pancreatic cancer cells 
Cell line SIM GEM SIM+GEM 
IC50 (µM) IC50 (nM) CI 
ASAN-PaCa 25±2.2 10±2.8 0.75±0.07 
BxPc-3 25±3.4 15±2.7 0.57±0.09 
MIA-PaCa2 3±1.2 20±5.4 0.82±0.01 
PANC-1 32±2.5 52±4.3 1.06±0.14 
The combination effect of simvastatin and gemcitabine in ASAN-PaCa, BxPc-3, MIA-PaCa2 and 
PANC-1 cells.  
The drug combination analysis was performed using the Chou-Talalay method. The graphs represent 
values of the combination index (CI) and they were generated automatically by using the CompuSyn 
software. Additive effects CI=1; Synergism CI<1; Antagonism CI>1; Measurement of viability of 
cells treated with simvastatin (SIM), gemcitabine (GEM) and combination (SIM+GEM) (refer to 
Table 10) for 72 h. Each value is represented as mean ± SD of three independent experiments. 
The results show that MIA-PaCa2 cells are about 10 times more sensitive to 
simvastatin compared to the other cell lines, due to the very low IC50 dose of 3 µM; 
the same applies to gemcitabine-sensitivity (Figure 10A). Due to the obtained CI 
results there is a synergistic effect for combination treatment resulting in enhanced 
cytotoxicity of gemcitabine in ASAN-PaCa, BxPc-3 and MIA-PaCa2 (CI＜1＝ but 
not in the most aggressive PANC-1 cells (CI＞1). Additionally, simvastatin had an 
only marginal effect on the viability of non-malignant human primary mesenchymal 
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stromal cells (MSCs) or immortalized human pancreatic ductal (CRL-4023) cells 
after 72 h treatment with simvastatin (Figure 10C, D). The above results indicate that 
simvastatin not only inhibits viability but also may reverse the chemotherapy 
resistance of PDA in vitro. 
 
Figure 10: Simvastatin is selectively cytotoxic in pancreatic cancer cells 
A. The human established PDA cell lines ASAN-PaCa, BxPc-3, MIA-PaCa2 and PANC-1 were left 
untreated (CO) or were treated with 50 nM gemcitabine (GEM), and the cellular viability was 
measured 72 h later with MTT assay. The gemcitabine resistance of the cells is indicated by a triangle 
above the diagrams. B. The human established PDA cell lines ASAN-PaCa, BxPc-3, MIA-PaCa2 and 
PANC-1 were left untreated (CO) or were treated with simvastatin at different time and concentrations 
as indicated, the cellular viability was evaluated with MTT assay. C. The non-malignant primary 
human cell lines CRL-4023 and MSCs were treated with different concentrations (10, 20, 30, 40, 50 
µM) for 72 h. D. The morphology of CRL-4023 and MSCs after 72 h treatment with 50 µM 
simvastatin was documented by microscopy at 100× magnification. Representative pictures are shown, 
and the bar indicates 100 µm.  (**P<0.01). 
To further confirm synergistic effects of simvastatin to gemcitabine sensitivity, the 
cells were treated with IC50 doses of simvastatin or gemcitabine or combinations 
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thereof. As a result, the cell viability significantly declined to approximately 50% 
with single treatment after 72 h in all cell lines examined. Combination treatment 
significantly decreased cell viability compared to single treatment (Figure 11A). 
Similarly, morphological analysis showed that cells exposed to gemcitabine partly 
preserved the cell morphology of parental cells regardless of cytotoxicity of 
gemcitabine. However, simvastatin and combined with gemcitabine treated cells 
showed conspicuously difference in the cell morphology (Figure 11B). In short, 
treatment with simvastatin strongly enhanced the cytotoxicity of gemcitabine in all 
cells lines examined. 
 
Figure 11: More aggressive pancreatic cancer cells response better to simvastatin 
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A. ASAN-PaCa, BxPc-3, MIA-PaCa2 and PANC-1 cells were treated as described above, and after 72 
h cellular viability was measured by MTT assay. The cell viability was measured as described in 
Figure 10. B. The morphology of ASAN-PaCa, BxPc-3, MIA-PaCa2 and PANC-1 cells treated with 
simvastatin, gemcitabine or both together (SIM+GEM) after 72h or untreated (CO). Representative 
pictures are shown, and the bar indicates 100 µm. Data are presented as mean ± SD. (**P<0.01).  
4.2 Simvastatin inhibits stemness and induces the differentiation potential of 
PDA in vitro 
To study the influence of simvastatin on self-renewal capacity, ASAN-PaCa, BxPc-3, 
MIA-PaCa2 and PANC-1 cells were treated and then seeded for colony and spheroid 
formation. Whereas simvastatin and gemcitabine alone significantly reduced the 
colony and spheroid formation in both size and number, the combination of both 
substances had more pronounced effects on PDA cells (Figure 12, 13).  
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Figure 12: Simvastatin inhibits colony formation of pancreatic cancer cells 
ASAN-PaCa, MIA-PaCa2, BxPc-3 and PANC-1 cells were treated as described in Figure 11, followed 
by re-plating of viable cells 72 h later at a low density (ASAN-PaCa: 1500 cells/well, MIA-PaCa2: 
400 cells/well, BxPc-3: 1000 cells/well, PANC-1: 800 cells/well) in 6-well plates. After two weeks, 
colonies containing more than 50 cells were counted using a dissecting microscope. The number of 
surviving colonies in the control group was set to 1, and the survival fraction is presented on the left. 
After the first generation (1st Gen) of colony formation, the cells were harvested and treated as 
described above, and then treated cells were re-plated at the same density described in 6-well plates. 
After an additional 2 weeks, clonogenic survival was analyzed as described above. Representative 
photographs of fixed and the colonies of four Coomassie-stained cell lines are presented on the right of 
the quantification (2nd Gen). (**P<0.01). 
To get information if the observed inhibition on colony and spheroid formation is 
maintained in a second passage after cell division, the survival colonies and spheroids 
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were harvested, and single, alive cells were isolated and seeded again for colony and 
spheroid formation. Also in this second-generation, and without additional 
simvastatin treatment, the spheroids and colonies were even stronger reduced than in 
the first-generation, suggesting that simvastatin indeed targeted CSCs in vitro. 
 
Figure 13: Simvastatin inhibits spheroid formation of pancreatic cancer cells 
ASAN-PaCa, MIA-PaCa2, BxPc-3 and PANC-1 cells were seeded at a clonal density (1.0-2.0×103 
cells/mL) in ultra-low attachment plates with serum-free but growth factor-containing medium for 
spheroid formation. The cells were treated as described in Figure 11, and 5 days later, the percentage 
of viable spheroids was determined (1st Gen). The quantity of spheroids in the control was set to 100%. 
Afterwards, the first generation spheroids were diluted to single cells, and equal quantity of live cells 
were re-plated at a concentration of 1.0-2.0×103 cells/mL. Upon spheroid formation 5 days later, the 
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cells were photographed at 100× magnification (on the right of the quantification) and quantified as 
described above (2nd Gen). The bar indicates 100 µm (**P<0.01). 
To analyze the influence of simvastatin on the differentiation potential, cells were 
incubated with the IC50 concentration of simvastatin for 72 h. Then osteo-
differentiation medium was added, to induce the osteoblastic differentiation. Ten 
days later, the cells were stained with BCIP/NBT to detect extracellular calcium 
deposits, which are secreted by mature osteoblasts. Such deposits were detected in all 
cells treated with simvastatin, but not in untreated cells (Figure 14A). Compared with 
non-simvastatin-treated control cells, the percentage of simvastatin-treated 
differentiated cells increased significantly to approximately 28% in ASAN-PaCa and 
BxPc-3 cells, followed by 23% in MIA-PaCa2 and 11% in PANC-1 cells (Figure 
14B). To underline these results, the expression of bone morphogenetic protein 4 
(BMP4) was evaluated, which is a marker for bone and cartilage development [188-
191]. Western blot analysis shows that BMP4 is already expressed in untreated cells, 
however, after treatment with simvastatin for 72 h, the expression of BMP4 was 
increased significantly in all cell lines examined (Figure 14C). Simvastatin also 
induced adipocyte differentiation, but to a much lower extent (Figure 14D), as 
concluded from the absence of a significant red lipid droplet accumulation after 
simvastatin treatment. These results indicate that simvastatin induces osteoblastic 
differentiation.  
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Figure 14: Simvastatin activates the differentiation potential 
A. ASAN-PaCa, BxPc-3, MIA-PaCa2 and PANC-1 cells were treated with simvastatin (SIM) for 72 h 
or were untreated (CO) as described in Figure 11, and incubated in osteogenic medium for 10 days. 
Osteogenic differentiation was detected by BCIP®/NBT. Differentiated cells present in dark color. 
The bar indicates 20 µm. B. Quantitative analysis of stained areas was confirmed by counting the 
number of differentiated cells in 10 vision fields for each group and cell line, and the presentation of 
the obtained data as percentage of differentiated cells (**P<0.01). C. Three days after induction of 
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osteogenic differentiation, western blot analysis of BMP4 expression was performed. β-actin served as 
internal control. D. ASAN-PaCa and BxPc-3 cells were treated with or without simvastatin, lipid-
droplets stained with Oil Red O. Differentiated cells present in red lipid droplet. The bar indicates 20 
µm. 
4.3 Simvastatin inhibits Hedgehog signaling 
Because covalent modification of Hedgehog proteins with cholesterol mediates auto-
cleavage and activation and Shh signaling has been implicated in tumorigenesis, I 
evaluated whether simvastatin may inhibit stemness by blocking Shh signaling in 
pancreatic cancer. To examine this hypothesis, the expression of the Hedgehog key 
members Shh, Smo, Gli1 and Sufu were detected before and after treatment of PDA 
cell lines with simvastatin and gemcitabine for 72 h followed by Western blot 
analysis. In all cell lines examined, simvastatin alone or combined with gemcitabine 
diminished the expression of Shh, Smo, and Gli1 and activated the expression of the 
Gli-inhibitor Sufu, whereas gemcitabine alone had no effect (Figure 15A). In contrast, 
gemcitabine alone did not modify the expression of these proteins significantly. To 
further examine the role of simvastatin in Hedgehog signaling, Shh was inhibited in 
PANC-1 cells by lipofection of specific Shh siRNA, whereas non-transfected cells or 
transfection of non-specific siRNA served as controls. First, the optimal siRNA 
concentration and time point after transfection were selected by time- and dose-
response kinetics and the detection of Shh expression by Western blot analysis of 
transfected and untransfected cells. By this way, a dose of 75 nM and a time point of 
3 days after transfection were identified as optimum (Figure 15B). These optimum 
siRNA conditions were then used to silence Shh expression in PANC-1 cells in the 
presence of the appropriate controls (Figure 15C). Interestingly, a knockdown of Gli1 
could be achieved by the knockdown of Smo, suggesting cross-regulation. 
Furthermore, the silencing of Shh had a similar effect to the cells as simvastatin, 
because it reduced the viability in a time-dependent manner (Figure 15D) and 
inhibited the formation of colonies (Figure 15E). Vice versa, the overexpression of 
Shh by transfection of an expression vector for Shh cDNA, partially inhibited the 
tumor-preventive function of simvastatin (Figure 15F, G, H).  
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Figure 15: Simvastatin represses Shh signaling in pancreatic cancer cells 
A. ASAN-PaCa, BxPc-3, MIA-PaCa2 and PANC-1were treated as described in Figure 11. After 72 h, 
the expression of Shh pathway related protein Gli1, Sonic Hedgehog (Shh), Smoothed (Smo) were 
measured by Western blot analysis in ASAN-PaCa, BxPc-3, MIA-PaCa2 and PANC-1 cell lines. β-
actin served as a control. B. The efficiency of human Sonic hedgehog siRNA (siShh) against Shh was 
evaluated by western blot assay in PANC-1 cells at different time points (24, 48, 72 h) and 
concentrations (25, 50, 75 nM), where non-specific siRNA (siCO) with irrelevant sequence was used 
as reference (75 nM) and β-actin as internal control. C. PANC-1 cells were treated as indicated for 72 
h, the effect of Shh siRNA on Gli1 and Smo were evaluated by Western blot. β-actin served as a 
control. Untreated (CO), non-specific siRNA (siCO), human Shh siRNA (siShh), simvastatin (SIM). D. 
Cell viability of PANC-1 cells after transfection of different concentrations (as indicated) of Shh 
siRNA for 24, 48 and 72 h. E. Survival fraction of PANC-1 cells after Shh siRNA knockdown with 
colony formation. non-specific siRNA (siCO), human Shh siRNA (siShh). F. The illustration shows 
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features of the Shh plasmid, which is derived from OriGene. G. PANC-1 cells were transfected with 
GFP-tagged plasmid of Shh, 48 h after transfection. G418 was added to the media at concentrations of 
1 mg/ml. After 72 h growth in medium, efficiency of transient transfection was evaluated under 
inverted fluorescence. Bright-field and fluorescent images of GFP expression are taken at 72 h after 
selection. The bar indicates 20 µm. Cells transfected with Shh plasmid were treated as indicated for 72 
h. Cells of all groups were harvested for Shh pathway related protein expression. Shh and 
Gli1 measurement expression by western blotting using β-actin served as an internal control. Human 
Shh plasmid (pcDNA3-hShh), simvastatin (SIM), Sonic hedgehog (Shh). H. Cell viability of Shh-
transfected PANC-1 cells treated with simvastatin (SIM), gemcitabine (GEM) or both together 
(SIM+GEM) for 72 h was measured by MTT-assay, as described in Figure 11. The data are presented 
as mean ± SD. (**P<0.01). 
To get knowledge which downstream signaling of progression markers may have 
been inhibited by simvastatin, to inhibit tumorigenicity, gene array analysis was 
performed. Whereas the expression of Shh genes, which was expected, was not 
significantly affected after simvastatin treatment (Figure 16A, B). Because the 
activation occurs on the posttranslational level, the expression of a broad panel of 
progression markers was inhibited (Figure 16C). Among them are CCNE, ZEB1, 
JAG2 and so on (Figure 16C).  
 
Figure 16: mRNA expression profiling of Shh signaling related genes in PANC-1 cells with or 
without simvastatin treatment 
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A. Heat map representation of the mRNA expression profiling showing selected genes within the Shh 
signaling pathway (annotated with KEGG pathway analysis) (*P<0.05). The red colors represent high 
expression and the blue colors indicated low expression within a scale from 4.5 to 7. B. Shh and Smo 
mRNA expression levels in PANC-1 cells 24h after treated with or without simvastatin (3 µM), as 
determined by qRT-PCR. The mean fold change of CO was set to 1. C. Heat map showed changes in 
the expression of Shh related progression markers in control (CO) and simvastatin (SIM) treatment 
groups. Shades of red and blue indicated high or low expression (see color scale). Experiments were 
performed in triplicate and data are shown as mean ± SD.  
4.4 Simvastatin inhibits tumor growth, invasion and Hedgehog signaling in 
vivo  
After establishing the functional effects of simvastatin in vitro, the results were 
further confirmed by using tumor xenotransplantation on fertilized chicken eggs. This 
in vivo system is naturally immunodeficient and enables the growth of well-perfused, 
tridimensional tumors with a pronounced tumor stroma, and with advantages to the 
mouse system regarding ethical reasons, bureaucracy and costs [192, 193]. The chick 
embryo needs 21 days breeding until hatching and xenografts do not grow before the 
blood vessels are well developed, so MIA-PaCa2 cells were transplanted at day 9 of 
development and injected the treatment or PBS in the control intravenously into chick 
blood vessels at days 12 and 15, until the tumor xenografts were harvested at day 18 
of embryo development (Figure 17A). The presence of tumors on eggs was 
determined and is shown as percentage of tumor takes. In parallel, the size of the 
tumors was measured by calipers. The results reveal that all treatments (simvastatin, 
gemcitabine and both together) reduced the tumor take rate and the tumor size 
compared to the control xenografts (Figure 17B). The tumor take rate and the size of 
xenografts from chick embryos, which received double treatment were significantly 
smaller than after each single drug treatment. To study the effect of the treatment to 
tumor invasion chick tissues of the chorioallantoic membrane (CAM) adjacent to the 
tumor xenograft were resected and genomic DNA was extracted to perform a PCR 
with primers for detection of human Alu sequences. We found that 81% of CAM 
specimens from untreated chick embryos were Alu-positive, followed by 19%, 69% 
and 0% of CAM specimens derived from chick embryos treated with simvastatin, 
gemcitabine or a combination thereof, respectively (Figure 17C). An internal control 
PCR reaction was performed with the same tissue but with chicken GAPDH primers, 
resulting in the detection of the same band intensity in all probes, suggesting equal 
conditions. These results correlate to 43% of positive expression of the proliferation 
marker Ki67, which was decreased to 32% after each single treatment with a 
significant further reduction to around 22% upon double treatment, as measured by 
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immunohistochemistry staining followed by microscopy and evaluation of the 
number of positive cells (Figure 17D). Likewise, simvastatin, but not gemcitabine, 
reduced the expression of Shh, Smo and Gli1 to 23.6%, 21.9% and 21.3% compared 
to 36.6%, 70.3% and 69.5% of that in CO respectively. No further reduction was seen 
upon combination with gemcitabine. These results suggested that simvastatin inhibits 
tumor engraftment, tumor growth, invasion, and the expression of proliferation 
marker Ki67 and Shh signaling related proteins Shh, Smo and Gli1 in vivo.  
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Figure 17: Simvastatin inhibits tumor growth and invasion in vivo and enhances gemcitabine 
efficacy 
A. Experimental procedure: 5×105 MIA-PaCa2 cells were seeded onto the CAM of fertilized chick 
eggs at day 9 of embryonic development (25 eggs per group). At day 12 and 15, the CAM was injected 
with 20 µL of normal saline (CO), or 60 µg simvastatin in 20 µL of normal saline (SIM), or 75 µg 
gemcitabine in 20 µL of normal saline (GEM), or 60 µg simvastatin together with 75 µg gemcitabine 
in 20 µL of normal saline (SIM+GEM). The tumor xenografts were harvested at day 18. B. 
Representative photographs of a developed xenograft on the CAM (black arrow) and a resected 
xenograft tumor were shown below. The rate of engraftment (tumor takes) and the volumes of 
individual tumors (dots) and the means of each group (bar) are shown (**P<0.01). C. Genomic DNA 
was extracted from CAM tissue (n=16) directly adjacent to the tumor xenografts, and a PCR with 
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 Days
Xenotransplantation
ResectionInjection
Injection
A
B
D
C
CO GEMSIM S+G
50 μm
Tu
m
or
 V
ol
um
e 
(m
m
3  )
400
100
0
CO SIM GEM SIM+GEM
200
300
**
** **
MIA-PaCa2 Tumor Take (%)
96 74 80 61
2 mm
CO SIM GEM SIM+GEM
CO
SIM
GEM
S+G
CO
SIM
GEM
S+G
CO
SIM
GEM
S+G
CO
SIM
GEM
S+G
Positive Cells (%)
****
**
**
**
**
**
**
**
0 20 40 60
Alu+
CAM Specimens
CO
SIM
GEM
S+G
2 4 6 8 10 12 14 16
Chicken GAPDH CO Sequences
M C
O
MIA-PaCa2 
CO:
81%
SIM:
19%
GEM:
69%
S+G:
0%
CAM Specimens
2 4 6 8 10 12 14 16M C
O Alu+
Human Alu Sequences
K
i6
7
Sh
h
Sm
o
G
li1
  62 
primers for human Alu sequences was performed. Genomic DNA in positive control (CO) was 
isolated from a tumor xenograft. The DNA marker is shown in the first line (Marker). D. Sections 
were prepared from the xenograft tumors and paraffin-embedded, and the expression of Ki67, Shh, 
Smo and Gli1 were examined by immunohistochemistry (left). The red or brown color represent 
positive signal. Representative images are shown. The scale bar indicates 50 µm. Quantification of 
Ki67, Shh, Gli1 and Sufu is shown on the right. The expression of positive cells was evaluated (right) 
by counting in 10 visual fields. 
4.5 Statins inhibits Shh signaling in primary PDA patient tumors 
To further examine the impact of statins in PDA patients, immunohistochemistry was 
performed and analyzed the Shh signaling related protein expression, Shh, Gli1 and 
Sufu, in patient tissue derived from normal pancreas (n=5) were analyzed, and PDA 
specimens derived from patients that had taken a statin such as simvastatin, 
atorvastatin and fluvastatin (n=34), or not (n=34) prior to resection. In normal 
pancreas, no Shh and Gli1 positive signal was found in the islets and ductal 
epithelium but evaluation of PDA tissue from patients without statin medication 
showed that the expression of Shh and Gli1 was 61% and 32% form specimens 
respectively, expression of Sufu was approximately 20% lower in PDA tissues 
compared with 25% Sufu positive in normal pancreas form specimens (Figure 18A, 
B). In contrast, expressions of Shh and Gli1 in tissue of patients with statin 
medication were almost absent. A significant higher Sufu positive signal was also 
detectable in PDA tissues from patients without statin medication (Figure 18A, B). 
Strong expression for c-Met, CXCR4 and vimentin in ductal cells and tumor stroma 
of patient tissue without simvastatin intake before surgery, whereas weakly positive 
staining for them in ductal cells and tumor stroma of PDA patient tissues with 
simvastatin intake (Figure 18C, D, Table 11, 12). These results confirm our in vitro 
and in vivo data and suggest that statin intake may prevent progression of PDA by 
inhibition of Hedgehog signaling. Basic on the results above, Shh signaling is 
aberrant high active in PDA cells, which has numerous and fundamental roles in 
proliferation, differentiation and migration in pancreatic cancer cells. After Shh is 
produced by PDA cells, covalent linkage of cholesterol to the Hedgehog proteins is 
required for their auto-cleavage, a necessary step in the processing and activation of 
the Shh. Inhibition of cholesterol biosynthesis mediated by simvastatin interrupts the 
post-translational modification of Shh and consequently prevents the inactive forms 
of Shh from binding to its receptor Patched, leading to inhibition of its downstream 
proteins Smo and nuclear transcription factor Gli1, which could enter the nucleus to 
active its target genes, such as Gli1, CD44 and CD133. Besides, simvastatin can also 
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impair Smo activation by directly reducing cholesterol level and induce expression of 
Gli1 inhibition protein Sufu in low-grade (Figure 18E). 
 
 
Figure 18: Shh signaling is inhibited in PDA specimens from patients with statin medication 
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A. Shh signaling related markers Shh, Gli1 and Sufu were detected by immunohistochemistry in 
normal pancreas (left) and PDA patients (right) specimens. Representative images are shown. The 
scale bar indicates 50 µm B. The numbers of dark brown cells in figure A were quantified in 10 visual 
fields, and the mean percentages ± SD are shown, **P<0.01. C. The patient tissue sections described 
were evaluated by immunohistochemistry for the expression of Shh, Gli1, Sufu and c-Met. Vimentin 
and CXCR4 in patient tissues were stained by immunohistochemistry. The scale bar indicates 50 µm. 
D. Quantification of Shh, Gli1, Sufu, c-Met, Vimentin and CXCR4 in figure C were determined by 
counting the number of dark brown cells in 10 visual fields, and the mean percentages ± SD are shown, 
**P<0.01. E. Role of simvastatin and cholesterol in the Shh signaling. Arrows suggest positive 
correlation, stopped lines is a sign of inhibition of the component and crosses indicate elimination of 
the inhibition of Smo and Gli1 when Shh presents. (**P<0.01). 
 
Table 11: Protein expression in tissue of PDA patients without statin medication 
 
Controls 
without  
statin  
treatment 
Patient ID. Shh Gli1 Sufu Vim CXCR4 c-Met 
HD 5933-1B 54.6 34.7 1.23 + + + 26.76 35.82 
HD 5956-1B 57.5 42.7 1.87 + + 4.16 38.22 
HD 6026-1A 61.6 40.6 0 + +  1.16 2.78 
HD 6076-1A 52.6 53.8 0.87 + + + 14.3 0 
HD 6095-1A 64.5 38.8 0.78 + + + 15.36 33.08 
HD 6102-1A 51.6 36.3 0.63 + + 28.84 17.32 
HD 6111-1A 54.7 46 0.33 + + + 9 20.58 
HD 6191-1A 52.7 54 0.28 + + 5.02 0 
HD 5735-1A 53.8 2.16 0 + + + 0 4.54 
HD 5835-1A 67.9 29.74 0 + +  29.58 20.84 
HD 5897-1A 52.42 10.82 0 + + + 17.82 40.5 
HD 5913-1B 51.4 9.6 0.36 + +  0 0 
HD 5921-1B 69.9 52.78 9.98 + + + 29.04 20.64 
HD 5934-1A 73.8 49.34 15.08 + + + 20.72 45.68 
HD 6014-1A 45.45 0 6.96 + +  18.56 12.4 
HD 6034-1A 61.78 44.5 3.42 + + + 26.22 0 
HD 6040-1A 66.42 56.8 13.22 + + + 42.22 32.48 
HD 6041-1A 69.26 11.98 9.64 + + + 30.7 32.76 
HD 6053-1B 63.82 45.56 4.58 + + + 14.52 17.24 
HD 6055-1C 69.56 47.42 2.03 + + + 15.82 19.72 
HD 6065-1A 79.96 47.58 7.5 + + + 0 67.2 
HD 6069-1A 63.7 57.24 5.06 + + + 21.74 0 
HD 6070-1A 57.68 20.48 0 + + + 25.52 30.16 
HD 6073-1A 44.25 24.86 0 + + + 8.98 0 
HD 6074-1A 58.82 10.16 0 + + + 25.52 29.36 
HD 6113-1A 56.58 17.76 7.62 + + + 17.44 59.36 
HD 6121-1A 58.5 36.28 0 + + + 4.96 15.96 
HD 6122-1A 71.18 7.34 8.36 + + + 18.2 44.82 
HD 6127-1A 62.44 33.22 1.54 + + + 27.6 38.82 
HD 6137-1A 72.583 23.88 9.28 + + + 28.74 29.02 
HD 6138-1A 67.667 19.18 0.42 + + + 0 49.48 
HD 6143-1A 60.2 20.3 14.36 + + + 0 0 
HD 6144-1B 51.72 22.52 9.68 + + + 44.46 37.76 
HD 6117-1A Necrosis Necrosis Necrosis Necrosis Necrosis Necrosis 
Average 60.62 31.77 4.09 +++ 17.4 23.7 
The expression of Shh, Gli1, Sufu, Vimentin (Vim), CXCR4 and c-Met was determined by 
immunohistochemistry microscopy. The intensity expression and percentage of positive cells was 
determined by counting the number of differentiated cells in 10 vision fields for each group. Visual 
  65 
judgment with Double-blind methods: extremely strong expression & very high percentage (≥75%) 
(+++), moderate expression & medium percentage (≤50%) (++) 
Table 12: Protein expression in tissue of PDA patients with statin medication 
Statin (mg/day) Patient ID. Shh Gli1 Sufu Vim CXCR4 c-Met 
Fluvastatin 80 mg HD 4911-1A 0 0 6.04 + + 2.16 0 
Simvastatin 40 mg HD 4921-1A 8.5 8.5 5.6 + + 1.9 0 
Simvastatin 40 mg HD 4952-1A 3.1 3.1 4.5 + + 0 0 
Simvastatin 30 mg HD 4953-1A 11.3 11.3 13 + + 0 0 
Simvastatin 20 mg HD 5101-1A 12.8 12.8 12.7 + Necrosis 0 
Simvastatin 40 mg HD 5393-1A 10.7 10.7 2.1 + + 0 0 
Simvastatin 40 mg HD 5459-1A 12.2 12.2 10.9 + + + 10.8 9.72 
Simvastatin 40 mg HD 5683-1A 1.7 1.7 7.5 + + 0 4.94 
Simvastatin 40 mg HD 4907-1A 16.48 16.48 5.08 + +  10.14 0 
Simvastatin 40 mg HD 4941-1A 14.56 14.56 0 + +  4.02 11.06 
Simvastatin 40 mg HD 4990-1A 4.24 4.24 2.66 + + + 0 3.96 
Fluvastatin 20 mg HD 5025-1A 0 0 5.1 + + + 7.28 0 
Simvastatin 20 mg HD 5117-1B 13.82 13.82 5.56 + + + 0.82 0 
Simvastatin 20 mg HD 5144-1A 21.24 21.24 4.46 + + + 16.96 13.78 
Pravastatin 20 mg HD 5433-1A 13.86 13.86 11.74 + + + 6.18 25.6 
Simvastatin 5 mg HD 5442-2A 17.08 17.08 19.82 + + + 19.74 49.82 
Simvastatin 40 mg HD 5488-1A 26.48 26.48 15.34 + + 15.66 0 
Simvastatin 20 mg HD 5511-1A 10.44 10.44 0 + +  12.78 29.32 
Fluvastatin 40 mg HD 5530-1A 20.9 20.9 8.04 + + + 9.4 34.64 
Atorvastatin 40 mg HD 5534-1A 17.06 17.06 7.04 + + + 15.34 39.54 
Atorvastatin 20 mg HD 5657-4A 21.36 21.36 9.72 + +  12.02 0 
Simvastatin 10 mg HD 5709-1A 18.58 18.58 5.1 + +  0 0 
Simvastatin 20 mg HD 5752-1A 23.04 23.04 16.46 + + + 4.34 50.34 
Atorvastatin 10 mg HD 5762-1A 1.3 1.3 5.02 + + 0 0 
Simvastatin 10 mg HD 5777-1A 14.06 14.06 13.92 + + + 8.06 5.8 
Simvastatin 20 mg HD 5858-1A 43.98 43.98 8.68 + + + 2.08 18.18 
Simvastatin 20 mg HD 5853-1B 23.18 23.18 9.96 + + + 13.46 42.28 
Atorvastatin 10 mg HD 5860-1A 33.9 33.9 1.35 Necrosis  0 22.9 
Atorvastatin 20 mg HD 5890-1A 3.38 3.38 2.28 + + + 1.52 0 
Simvastatin 20 mg HD 5906-1A 36.62 36.62 13.62 + + + 7.6 11.68 
Simvastatin 20 mg HD 5936-1A 9.66 9.66 9.54 + + + 14 25.78 
Simvastatin 20 mg HD 5983-1A 15.32 15.32 16.9 + + + 0 0 
Atorvastatin 20 mg HD 6051-1A 8.42 8.42 5.12 + + + 0 0 
Simvastatin 20 mg HD 6018-1A 15.5 15.5 13.92 + + + 12.18 21.18 
Average 14.85 6.75 8.20 ++ 6.3 12.9 
The expression of Shh, Gli1, Sufu, Vimentin (Vim), CXCR4 and c-Met was determined as described 
in Table 11  
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5. DISCUSSION AND CONCLUSION  
5.1 Discussion 
Pancreatic cancer is one of the worst prognoses of malignant diseases and the third 
leading cause of cancer death in the USA [1]. My experimental data suggest that 
statin medication may be helpful in prevention and treatment of this fatal disease. The 
clinical relevance of mechanistic studies on the incidence and progression of 
pancreatic cancer is unclear, because some studies suggest promotion, others the 
inhibition of tumor growth. Likewise, several clinical trials demonstrated that statin 
use was associated with a higher cancer risk [137]. For example, pravastatin was 
associated with an increase in breast cancer risk in one clinical trial [194], and total 
cancer and gastrointestinal cancer risk in another clinical trial [195], but pravastatin 
showed antitumor effect in an rat mammary gland carcinoma model. However, no 
other large randomized controlled trials of statins demonstrated an altered risk of 
cancer incidence [196-198]. Some authors emphasized that there was no evidence 
between the use of a statin and the development of colon, pancreatic or prostate 
cancer [139, 140, 152]. In the seven types of statins approved by the U.S. FDA, 
pravastatin is the most hydrophilic statin compared to the other statins, and 
differences in hydrophobicity may have clinical significance with respect to factors 
such as cancer risk. The different pharmacokinetic properties between hydrophilic 
and hydrophobic statins demonstrated differential outcomes on cancer risk [199, 200] 
and may explain the association between pravastatin use and high risk of cancer in 
two randomized controlled trials [194, 195]. Differences in hydrophobicity may be 
also the reason for inhibition of intracellular Ras protein translocation as observed for 
all statins except of pravastatin [129, 130, 201]. Contrary to concerns about the 
carcinogenicity of statins, growing clinical and epidemic evidence reveal that 
simvastatin in fact have a chemopreventive potential against multiple cancers [114], 
including colorectal, liver and prostate cancers [119, 202, 203], as well as pancreatic 
cancer [204]. These findings suggest that simvastatin may be a potential efficient 
agent to CSCs. This study provides evidence that simvastatin not only strongly 
inhibited the viability of pancreatic cancer cells but also sensitized established 
pancreatic CSCs to gemcitabine-mediated cytotoxicity by inhibiting cholesterol 
mediated Shh signaling pathway. 
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5.1.1 Simvastatin primarily targets highly aggressive cells and is well tolerated 
To determine whether simvastatin primarily affects more aggressive cells, I used a set 
of established PDA cell lines with documented low, medium or high aggressiveness. 
My results showed that simvastatin mainly affected the more aggressive and 
gemcitabine-resistant cells but not the less-resistant or non-malignant cells. Similar 
results were found with several other cell lines of different tumor entities [205]. As 
most chemotherapeutic drugs have severe side effects, my observation of different 
sensitivity of non-malignant cells and cancer cells to simvastatin might have 
important effects on the option to use statins as co-treatment in cancer, similar to the 
already wide medication for treatment of hypercholesterolemia. To confirm my 
observation that simvastatin mainly attacks the highly aggressive pancreatic cancer 
cells, the effects of simvastatin on non-malignant pancreatic duct cells and 
mesenchymal stem cells was examined. I found that simvastatin exhibited slight 
cytotoxicity to these primary cells at a therapeutically active concentration of 50 µM 
in vitro. Likewise, simvastatin did not induce adverse side effects in chick embryos in 
vivo. Thus, simvastatin indeed may hold great potential benefits for both cancer 
prevention and treatment.  
We proceeded to evaluate the effect of simvastatin on the therapeutic efficacy of 
gemcitabine. My results demonstrated that simvastatin significantly enhanced the 
ability of gemcitabine to reduce cell viability. A significant greater combined effect 
of simvastatin and gemcitabine combination compared to the single substances was 
also observed in PANC-1 cells, although it did not indicate synergism. This apparent 
contradiction can be explained by the T.C. Chou’s theory, since synergism is 
determined by CI values instead of P values [184]. My in vitro data were further 
supported by my in vivo findings showing that simvastatin led to complete inhibition 
of tumor growth, engraftment and metastasis when administered in conjunction with 
gemcitabine.  
5.1.2 Simvastatin inhibits CSCs self-renewal and induces differentiation in pancreatic 
cancer cells in vitro 
We demonstrated that simvastatin strongly reduces the self-renewal potential of 
established and primary CSC cells by inhibition of colony and spheroid formation. 
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Similar results were recently found in breast cancer [133]. Since inhibition of cloning 
efficiency is generally considered the hallmark of differentiation, whether simvastatin 
induces osteogenic and adipocyte differentiation potential was further investigated in 
four established pancreatic cancer cell lines. It was found that simvastatin treatment 
activated the differentiation potential. These findings are consistent with recent 
studies, which reported that simvastatin induced osteogenic differentiation of Murine 
embryonic stem cells [188-190]. Similar results were also found in human 
periodontal ligament stem cells in vitro and in vivo [191]. 
I assume that these results may be partly due to the observed simvastatin-mediated 
inhibition of Sonic hedgehog activity, which is highly expressed in PDA aggressive 
CSC-like cells, which has been suggested that inhibition of Hedgehog signaling 
enhances delivery of chemotherapy in pancreatic cancer [56, 81, 206]. Indeed, almost 
all stages of PDA are associated with Hedgehog signaling [51], and activation of Shh 
and Smo is crucial for the development of pancreatitis [56, 207]. These events may 
be prevented by treatment with simvastatin, which thereby may reduce the risk of 
developing PDA or the progression of existing PDA.  
5.1.3 Simvastatin impairs Hedgehog signaling 
The mechanisms involved in the anti-proliferative and anti-CSC actions of 
simvastatin are not fully understood. Several lines of evidence indicate that an 
inhibitory effect on the Hedgehog signaling may be a major event in these antitumor 
actions [207-212]. The PDA cell lines have been reported to have high levels of Hh 
expression [213, 214]. Pancreatic adenocarcinoma cells can produce increasing 
amounts of Shh, and MIA-PaCa2 cell line showed higher Hh expression [215]. This 
is probably why simvastatin was maximally effective in MIA-PaCa2 cells, which is 
considered as one of the most malignant pancreatic cancer cell line. 
Because of Hh signaling plays an important role of in cancer development, increasing 
studies are focus on safe and specific Hh inhibitors of clinical use [216]. By 
inhibiting HMG-CoA reductase activity, simvastatin is capable of blocking 
cholesterol synthesis, which was recognized essential in post-translational 
modification of Hedgehog proteins. Similar results were found in transgenic mouse 
models of the Smith−Lemli−Opitz syndrome, which revealed that cells defective in 
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cholesterol biosynthesis did not respond to Shh [217]. Moreover, cholesterol can 
directly or indirectly stimulate Smo activity [217, 218], a critical component of the 
Hh signal transduction. Contrarily, reduced cholesterol levels can also 
impair Smo activation [207]. Vice versa, high cholesterol levels are associated with 
accumulation of Smo on the plasma membrane, which is the first step to the 
activation of Smo [208]. Besides, some oxygenated derivatives of cholesterol can 
bind to Smo collaboratively with two well-known agonists, purmorphamine and SAG, 
which play key roles in Hh signaling [219]. In cancer treatment, Sufu is not usually 
targeted by medical compounds, however it plays an important role in clinical 
therapy since it is a tumor suppressor gene, mutations in Sufu could lead to the 
development of numerous types of cancer. In this study, my results show that the 
expression of Sufu is increased by simvastatin treatment. The reason of this alteration 
is not entirely clear. But the fact that Smo activates Gli transcription factors through 
the release of Gli from Sufu may explain this still unexplored mechanism [66].  
5.1.4 Simvastatin has a preventive effect on the development of PDA.  
I observed that simvastatin-treated PDA cells show an impaired potential for self-
renewal due to the inhibition of spheroid and colony formation, and impaired tumor 
engraftment in vivo. These results are in accordance with recent data obtained in 
transgenic mouse models of pancreatic cancer, which demonstrated that daily i.p. 
injection of 10 mg/kg simvastatin significantly delayed the progression of mPanINs 
in LsL-KrasG12D; Pdx1-Cre mice [135]. The concentrations of simvastatin 
administered to mice may be relevant for humans, because simvastatin dose-
dependently exerted a significant chemopreventive potential in lung cancer in COPD 
patients [220]. The daily intake of 30 mg statin was associated with a lower risk 
of cancer related death, especially among simvastatin users. After PDA diagnosis, the 
use of simvastatin indicated a longer survival among patients with non-metastatic 
PDA [121]. A recent clinical study also suggested that statins show a promising 
effect on "long-term response" to gemcitabine-erlotinib chemotherapy in 
unrespectable pancreatic cancer [221]. 
My data obtained with the chicken egg model adds important information to the 
increasing evidence that simvastatin indeed may be able to inhibit the growth of PDA 
in patients, as indicated in recently published clinical studies, which reported that 
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patients who had intake moderate-high-intensity doses of simvastatin have a 
significantly better survival compared to those who received low-intensity doses 
[124]. Statin use was associated with longer overall survival (OS) of PDA patients 
and significantly decreased the risk of pancreatic cancer and there was a significant 
dose-effect of statin use for the risk of pancreatic cancer [149, 161]. However, in 
contrast to my study, none of these studies addressed the efficacy of simvastatin 
toward CSC-like PDA cells by Hedgehog signaling. 
My results obtained with PDA xenografts on chicken eggs, as well as my 
examinations of tissues from patients who had or had not taken simvastatin before 
surgery suggest that simvastatin strongly reduces the expression of Shh and Gli1. The 
effect of simvastatin on Hedgehog signaling in PDA has to my knowledge never been 
studied before. The obvious clinical relevance of my findings has recently been 
confirmed by several studies in colorectal cancer [222], prostate cancer [126], renal 
cell carcinoma [143] and lung cancer [154, 164]. These authors support my view and 
conclude that cancer patients may benefit from simvastatin medication. 
5.2 Conclusion 
My study demonstrates that simvastatin exhibits strong activity against pancreatic 
CSCs, which may be mediated by inhibition of the Shh signaling pathway. 
Importantly, simvastatin does not present obvious toxicity to non-malignant cells. 
Besides, the self-renewal of pancreatic CSCs is inhibited and the differentiation 
potential is activated in vitro. Tumor engraftment, growth, invasion and the activation 
of Shh signaling are inhibited in vivo. Immunohistochemistry of human pancreatic 
cancer tissue from patients that received a statin prior to surgery or not demonstrated 
that the activation of Shh signaling and progression markers was inhibited by statin 
medication. Therefore, I suggest simvastatin to be a promising adjuvant for 
prevention of PDA and to improve the efficacy of chemotherapy as a robust, cost-
effective and well-tolerated drug.  
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6. SUMMARY 
Pancreatic ductal adenocarcinoma (PDA) is a disease with an exceptionally poor 
prognosis, high therapy resistance and poor effective therapeutic options. Advances 
in therapeutic treatments are urgently required. Cancer stem-like cells (CSCs), 
capable of unlimited self-renewal, have been proposed as a mechanism for cancer 
growth, therapy resistance and metastasis, involving PDA. Besides a function in 
normal tissue development, Sonic hedgehog (Shh) is highly expressed at all stages of 
human PDA. Recent data demonstrate that the expression of Shh is highly 
upregulated in CSCs and regulates them. Simvastatin, which is widely prescribed as 
cholesterol-lowering drug, was shown to inhibit tumor growth, metastasis and cancer-
specific mortality in some studies, but the available data are not consistent. Most 
importantly, the hypothesis of my thesis, namely that simvastatin attacks 
pancreatic CSCs by inhibition of Sonic hedgehog signaling was never examined 
before. In my thesis, I evaluated the effect of simvastatin on 3 established and 1 
primary PDA cell lines, as wells as non-malignant pancreas cells and mesenchymal 
stromal cells from human bone marrow. Results from cell viability assays show that 
simvastatin significantly reduces viability even at low concentration in CSC-enriched 
cell lines. I observed synergetic effects on pancreatic cancer cells upon combination 
of simvastatin with gemcitabine in vitro. Colony and spheroid assays indicated that 
simvastatin inhibits self-renewal, with an even stronger effect upon combination with 
gemcitabine. In addition, simvastatin significantly induced the differentiation 
potential. My results obtained with pancreatic cancer xenografts transplanted on the 
CAM of fertilized chicken eggs show that simvastatin inhibits tumor growth and 
metastasis in vivo. Importantly，no pronounced toxic side effects of simvastatin to 
non-malignant cells or chick embryos occurred. My further experiments suggest that 
the underlying mechanism of simvastatin is associated with inhibition of cholesterol 
biosynthesis, which is essential for post-translational modification and thereby Sonic 
hedgehog activation. Simvastatin alone or combined with gemcitabine diminished the 
expression of Shh and related proteins Smo, Gli1 and activated the expression of the 
Gli-inhibitor Sufu. Likewise, the siRNA-mediated inhibition of Shh expression 
mimicked the simvastatin effect, whereas it´s overexpression prevented it. I 
confirmed these in vitro and in vivo findings in tissue of patients who did (n=34) or 
did not (n=34) receive simvastatin prior to surgery. Thus, the expression of Shh, its 
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downstream signaling protein Gli1, along with the levels of progression markers 
Vimentin, CXCR4 and c-Met were lower in PDA tissues from patients with statin 
medication. Therefore, I conclude that simvastatin, as a robust, cost-effective and 
well-tolerated drug for prevention of hypercholesterolemia, may also be suited to 
prevent PDA and to improve the efficacy of standard therapy in patients suffering 
from PDA. 
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